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Abstract
Metal dyshomeostasis in the brain is an underlying feature of Alzheimer’s disease. The further
understanding of metal distribution in the brain is critical to further explore the role of metals in AD. The
specific causes and effects that result in metals influencing the build-up of toxic, insoluble amyloid-beta
plaques remain ambiguous. Treatment of cannabidiol (CBD) to APPxPS1 mice has been studied to
prevent social recognition deficit and has the potential for a preventative treatment for Alzheimer’s
disease (AD). This project analyses the distribution of Cu, Zn and Fe in healthy and affected transgenic
APPxPS1 mice brains and produces comprehensive metal concentration maps outlining any
accumulations and/or trends emerging. This project studies how metal distribution is affected when
transgenic mice with Alzheimer’s and wild-type (WT), healthy mice are treated with cannadibiol. Four
groups of mice will be studied for comparison consisting of 14 APPxPS1 mice exhibiting AD (7 treated
with CBD and 7 untreated) and 16 wild-type, healthy mice (8 treated with CBD and 8 untreated). The thirty
sample mice brains were prepared and cryosectioned and analysed using laser ablation inductively
coupled plasma mass spectrometry where metal concentrations were quantified using matrix-matched
standards. Metal distribution maps were created and spatial analysis conducted to compare areas of
metal deficiency or accumulation between the four groups. The metal concentration maps highlighted
trends for each metal in the brain, such as Zn enrichment in the corpus callosum. The hippocampus and
cerebellum are identified as regions with enhanced plaque pathology and average concentrations of
metals between these regions were compared. These areas can indicate potential regions of increased
(or decreased) metal activity which could be the result of failed mechanisms to control metal ion
homeostasis. The comparison of metal concentrations in the whole brain, hippocampus and cerebellum
of APPxPS1 with AD to WT mice identified a lower average concentration of metals in an AD brain.
Treatments of CBD to both APPxPS1 mice and WT mice resulted in a higher metal concentration on
average. Therefore, it is indicated that metals in AD affected brains are deficient and metal-targeting
treatments, such as metal chelators, could prove to be therapeutic for AD. The treatment of CBD was
found to increase the average metal concentration in WT brains to much higher levels which could
potentially lead to toxicity. The findings in this study pave the way for future research to further explore
metal deficiency in AD and treatments specifically targeting metals. The treatment of CBD can also be
further explored in both its therapeutic heightening of metal concentrations in an AD brain and its
potentially damaging heightening of metal concentrations in WT.
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ABSTRACT
Metal dyshomeostasis in the brain is an underlying feature of Alzheimer’s disease. The
further understanding of metal distribution in the brain is critical to further explore the role of
metals in AD. The specific causes and effects that result in metals influencing the build-up of
toxic, insoluble amyloid-beta plaques remain ambiguous. Treatment of cannabidiol (CBD) to
APPxPS1 mice has been studied to prevent social recognition deficit and has the potential for
a preventative treatment for Alzheimer’s disease (AD). This project analyses the distribution
of Cu, Zn and Fe in healthy and affected transgenic APPxPS1 mice brains and produces
comprehensive metal concentration maps outlining any accumulations and/or trends
emerging. This project studies how metal distribution is affected when transgenic mice with
Alzheimer’s and wild-type (WT), healthy mice are treated with cannadibiol. Four groups of
mice will be studied for comparison consisting of 14 APPxPS1 mice exhibiting AD (7 treated
with CBD and 7 untreated) and 16 wild-type, healthy mice (8 treated with CBD and 8
untreated). The thirty sample mice brains were prepared and cryosectioned and analysed
using laser ablation inductively coupled plasma mass spectrometry where metal
concentrations were quantified using matrix-matched standards. Metal distribution maps were
created and spatial analysis conducted to compare areas of metal deficiency or accumulation
between the four groups. The metal concentration maps highlighted trends for each metal in
the brain, such as Zn enrichment in the corpus callosum. The hippocampus and cerebellum
are identified as regions with enhanced plaque pathology and average concentrations of
metals between these regions were compared. These areas can indicate potential regions of
increased (or decreased) metal activity which could be the result of failed mechanisms to
control metal ion homeostasis. The comparison of metal concentrations in the whole brain,
hippocampus and cerebellum of APPxPS1 with AD to WT mice identified a lower average
concentration of metals in an AD brain. Treatments of CBD to both APPxPS1 mice and WT
mice resulted in a higher metal concentration on average. Therefore, it is indicated that metals
in AD affected brains are deficient and metal-targeting treatments, such as metal chelators,
could prove to be therapeutic for AD. The treatment of CBD was found to increase the
average metal concentration in WT brains to much higher levels which could potentially lead
to toxicity. The findings in this study pave the way for future research to further explore
metal deficiency in AD and treatments specifically targeting metals. The treatment of CBD
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can also be further explored in both its therapeutic heightening of metal concentrations in an
AD brain and its potentially damaging heightening of metal concentrations in WT.
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INTRODUCTION
Alzheimer’s disease (AD) is the most common form of dementia and combined they are
determined to be the second leading underlying cause of death in Australians in 2013 (ABS,
2016). There is no clear pattern of inheritance therefore age is considered to be the largest
risk factor for AD where 96% of people identified as having dementia or Alzheimer’s disease
in 2009 were over the age of 65 (ABS, 2016). Females are more likely to be affected by AD
with the sex ratio between 2009-2013 being 50 male deaths per 100 female deaths (ABS,
2016). The disease targets brain function associated with memory, coordination, learning and
even emotions. It results in a slow decline of movement, speech, memory and basically every
bodily function we take for granted until another perhaps virus targets the weakened immune
system and the individual dies. There is currently no cure for AD and understanding of the
true cause of the disease is still being unlocked. The number of deaths caused by this disease
rose by 32% between 2009-2013 which creates an alarming socioeconomic problem that
needs to be addressed as quick and efficiently as possible (ABS, 2016).

Figure 1 - Comparison of normal and diseased brain cell interaction, highlighting amyloid plaque and neurofibrillary
deposition (BrightFocus Foundation, 2000)

Alzheimer’s disease is characterised by the two main deposits of amyloid plaques and
neurofibrillary tangles. These deposits hinder a neurotransmitters ability to communicate
1

effectively between neurons across a synapse, which is a connection between brain cells. This
interrupts healthy brain cell activity and results in cell death. Plaques occur outside the
neuron and neurofibrillary tangles occur inside the neuron, (Figure 1). Plaques are caused by
the build-up of the sticky protein: amyloid-beta. This protein normally aggregates into a
soluble mass in the brain whereas in the formation of plaques it aggregates into a hard,
insoluble mass that destroys synapses and leads to cell death. The mutation of amyloid
precursor protein (APP) leads to this characteristic insoluble build-up of amyloid-beta into
plaques. Amyloid plaque build-up is widely accepted to be a pathological hallmark in AD
and plaque pathology has shown they are mostly concentrated in the cerebellum, neocortex,
amygdala and hippocampus (Hardy et al. 2002).
APPxPS1 mice model exists as a model of AD and exhibit the symptoms, such as memory
loss, commonly seen in AD (Duncan et al. 2012). The APPxPS1 mice are used in this study
to act as a model of AD as close as possible to the human brain with AD. These mice
overexpress the APP to produce a fast-tracked model of AD in a mouse brain. Metals,
specifically Cu, Fe and Zn, have been studied to interact with amyloid-beta to influence
fibrillization and toxicity (Tiiman et al. 2013). Copper, Fe and Zn are implicated in AD
processes but the full understanding of their link with AD is still unknown. Metals are often
concentrated in areas of increased plaque pathology and it is therefore necessary to further
understand their interaction with AD processes to unlock deeper understanding of AD itself.
Therefore, the aim of this project is to investigate whether changes in Cu, Fe and Zn can be
detected in APPxPS1 mice by comparing them to healthy controls.
Furthermore, CBD has been proposed as a possible treatment for AD and has been studied to
prevent social recognition deficit in APPxPS1 mice (Cheng et al. 2014). The treatment of
CBD to AD affected brains can be studied in regards to metal distribution to further implicate
metals in AD processes. Another aim of this project is to assess the effect of CBD on metal
distribution in the brain of APPxPS1 mice and WT mice. To address these aims 30 mice were
cryosectioned, 14 of which were APPxPS1 mice with AD (7 treated with CBD and 7
untreated) and 16 of which were WT, healthy mice (7 treated with CBD and 7 untreated). The
sectioned brains of the 30 mice were analysed using laser ablation inductively coupled
plasma mass spectrometry (LA ICP-MS). Imaging software was then utilised to quantify the
2

data from intensity (laser counts per second) into comprehensive metal concentration (ppm)
maps of Cu, Zn and Fe in each brain. Spatial analysis enabled calculation of the average
metal concentrations in the whole brain, hippocampus and cerebellum. This allowed
extensive comparison between metal concentration maps and statistical analysis from the data
extracted using spatial analysis.
In the first chapter the role of metals in AD will be discussed as well as the role of metals in a
healthy brain. The use of the LA ICP-MS method is then discussed in regards to its role in
producing the data necessary for the metal concentration maps. The methodology for sample
preparation and analysis is then outlined in chapter 2. The results achieved in this study will
be discussed in chapter 3 for the whole brain, hippocampus and cerebellum for each metal
(Cu, Fe and Zn). The conclusions deduced from the results will be discussed in Chapter 4.
References and appendices will follow Chapter 4.
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CHAPTER 1 – LITERATURE REVIEW
1.1 METALS IN THE BRAIN
Metal ions are present in strict quantities in the brain and facilitate many vital processes and
metal-ion homeostasis is critical for normal brain function. Specifically, Duce et al. (2010)
recognises metals as the facilitators and key maintenance for ‘enzymatic activities,
mitochondrial function, myelination, neurotransmission as well as learning and memory’.
Brain cells have therefore developed mechanisms to maintain metal ion homeostasis. A
critical spike in metal ion levels can quickly result in neurotoxicity and a drop can result in
severe deficiencies that cause numerous problems. A study by Ramos et al. (2014) attempted
to provide a standard for “normal” amounts of metals in the brain using ICP-MS for analysis
and found that the highest levels of Zn were found in the hippocampus and the highest levels
of Cu in the putamen. These regions of the brain, especially the hippocampus, are directly
affected in AD and are intrinsic to memory and motor control. Trace element distribution is
notoriously heterogeneous in the brain, as supported by Ramos et al. (2014), and the ability to
provide comparative bio maps of metals will be crucial to further understanding their role in
AD.

1.2 OXIDATIVE STRESS AND METAL FUNCTION
The redox capacity of Cu in the brain is used for a variety of normal brain functions and Bush
et al. (2003) suggests that this rapid transition of Cu between oxidation states is central to the
role of Cu in cuproenzyme activity. However, the interrupted metabolism of Cu can result in
‘excessive free radical production and associated increases in neuronal oxidative stress’
(Bush et al. 2003). Therefore, the homeostasis of Cu in the brain is crucial for oxidative
normality in necessary functions. Bush et al. (2003) also links the associated oxidative stress
caused by Cu metabolism failure to the role of Cu in its interaction with amyloid beta to form
plaques. Zinc and Fe are also highly implicated by Bush et al. (2003) and Greenough et al.
(2013) in the formation of plaques where the highest concentrations of the metals are found
in regions with enhanced plaque pathology such as the aforementioned neocortex,
hippocampus and amygdala. The accumulations of Cu, Zn and Fe would be an indicator for a
mechanism in metal metabolism failing and is therefore necessary to map Cu, Zn and Fe
4

accumulations in the brain to locate possible plaque accumulations and other such areas of
interest. Figure 2 doedaa

Figure 2 - Example of reactions to form damaging hydroxyl radicals (Khalil et al. 2011)

The neurotoxicity of these oxidised states is also reinforced in Roberts et al. (2012) where the
production of hydrogen peroxide and generation of hydroxyl radicals by Fenton chemistry are
implicated. The oxidised forms of Fe or Cu produce hydrogen peroxide when binding
amyloid-beta proteins due to a reduction of molecular oxygen (Roberts et al. 2012). Figure 2
displays the Fenton chemistry implicated in Roberts et al. 2012 where hydrogen peroxide and
reduced Fe or Cu generate hydroxyl radicals. Hydroxyl radicals are extremely hazardous in
the brain and are characteristic of AD neuropathology. Another mechanism that is potentially
leading to hydrogen peroxide production is the increase of cytoplasmic Cu (Freedman et al.
1989).
Ceruloplasmin is a protein found in plasma that is capable of transporting Cu, has an
important redox capacity and has also been linked to the metabolism of Fe. Snaedal et al.
(1998) found that the ceruloplasmin oxidative activity in plasma of AD patients was greatly
reduced yet the copper concentrations between patients and their controls were not
significantly different. Bush et al. (2003) found that patients with AD have low ceruloplasmin
levels as well as lower levels of a copper containing enzyme superoxide dismutase (SOD1).
Superoxide dismutase is described as being ‘key in suppressing the amounts of superoxide
anion radicals (Snaedel et al. 1998). The lower levels of SOD1 actually point to a deficiency
in intracellular Cu rather than an accumulation which further validates the need to not only
5

look for metal accumulation but rather trends of areas with no trace of metals/extremely low
traces in the bio maps created in this project. The deficiency of Cu implicated in some journal
articles as compared to highly elevated levels of Cu studied in other journal articles can be
married through the paper of White et al. (2006). It was found in this paper that extracellular
Cu levels are elevated in relevance to the areas of the brain most implicated in AD pathology
whereas subcellular Cu levels can be deficient due to decreased activity of several
cuproenzymes and low ceruloplasmin in a brain with AD (White et al. 2006). This links in
with reduced SOD1 levels in AD brains correlated with reduced Cu levels as also found in
Snaedel et al. (1998).

1.3 THE ROLE OF METALS IN AD
The blood brain barrier (BBB) acts as a membrane separating the cerebrospinal fluid (CSF)
from the blood, and is intrinsic to the movements of metals across it (Duce et al. 2010). The
non-bound forms of metals such as zinc (Zn), iron (Fe) and copper (Cu) are extremely
hazardous in the brain and are therefore highly regulated by the BBB. The mechanisms that
brain cells have developed to keep metal ions at equilibrium after permeating the BBB can be
disrupted and the chance of neurotoxicity developing and causing such diseases as
Alzheimer’s increases dramatically. Duce et al. (2010) demonstrates an example of this
where decreased mitochondrial activity in a brain with AD results in reduced metal uptake of
Cu and Zn (Figure 3). This creates an accumulation of Cu and Zn over time due to the
transporter mechanisms failing to distribute them around the brain. The synaptic Zn and Cu
are being transported in the healthy brain by various mechanisms such as the amyloidprecursor protein (APP) absorbing Zn and reducing metal accumulation (Figure 3). Duce et
al. 2010 recognise that the appearance of free synaptic copper and zinc is maintained by a
number of other ways including putative energy-dependent reuptake mechanisms.

6

Figure 3 - Models of zinc and copper in the glutamatergic synapse in health and Alzheimer's disease (Duce, James et
al, 2010)

Decreased mitochondrial activity results in amyloid plaque deposition which inhibits the
APPs ability to effectively decrease Zn concentrations and interferes with many other
mechanisms in place to reduce metal accumulations. Therefore, recognising a trend in metal
accumulations across transgenic mice brains with Alzheimer’s Disease (AD) can result in a
better understanding of where these mechanisms are failing. The amyloid precursor protein is
found most abundantly in the synapses of neurons and mutations of this protein could be
implicated as a cause of amyloid-beta (AB) plaque build-up (Hardy et al. 2002). Maynard et
al. (2002) found that an overexpression of the carboxyl-terminal fragment of the amyloid
precursor protein, containing AB, results in significantly decreased levels of Cu and Fe in a
7

healthy transgenic mouse brain. Additionally, the study analysed the transgenic mouse brains
of the Tg2576 model, which uses an overexpression of APP, and found Cu to be significantly
reduced whereas Fe was not affected in the levels of metals in the brain prior to the formation
of amyloid plaques. These results support the implication of APP and AB in maintaining
metal homeostasis in the brain and that a failure and/or mutation of these proteins can result
in metal accumulation or deficiency (Maynard et al. 2002). Copper is again implicated in
APP trafficking in Acevedo et al. (2011) through promoting a ‘redistribution’ of APP from a
perinuclear localisation to a wider distribution. Acevedo et al. (2011) found that Cu promoted
an increase in cell surface APP by increasing its exocytosis and reducing its endocytosis
respectively. Therefore, Cu heavily dictates APP’s locality and reach and accumulation of Cu
could indicate increased localities of APP.
The metal binding protein ‘metallothionein’ has been studied to provide a level of resistance
to damaging concentrations of metals in the brain (Freedman et al. 1989). It binds with Cu to
reduce the amount of detrimental free radicals and effectively balances the level of toxic
metals in the brain. The success of this protein is controlled by the degree of metal exposure
and therefore warrants the bio-mapping of metals in the brain to identify areas more at risk to
metal exposure. Copper, Fe and Zn are intrinsically linked with plaque pathology and
analysing the interaction of these metals with AB plaques will further lead to a greater
understanding of AD. Lovell (1998) measured Cu, Fe and Zn in the rims and cores of senile
plaques and in the neuropil of the amygdala of patients with AD and compared them with
age-matched, healthy control patients using micro particle-induced X-ray emission (microPIXE). Copper, Zn and Fe were found to be significantly increased in the rims of plaques in
patients of AD when compared with the neuropil of patients with AD. Lovell et al. (1998)
made the conclusion that Cu, Zn and Fe can accelerate the aggregation of the AB peptide.
Therefore, mapping the distribution of metals in a brain may provide indications of where
clusters of AB plaques will appear.
Copper and Fe naturally increase with age and could dictate a starting point for AD to
flourish. Squitti et al. (2002) suggests that serum Cu measurement may prove to be a
diagnostic marker for AD. Recognising and mapping a normal distribution of metals in the
brain as well as the distribution in affected brains, particularly Cu, Zn and Fe, could aid
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studies and diagnostic markers in detecting and treating AD. An interesting area of study to
be addressed is that of the difference in metal metabolism between the sexes due to the
significantly higher incidence of AD in women (Maynard et al. 2006). It was found by
Maynard et al. (2006) that women have lower Cu levels of men regardless of age and
APP/AB expression (Maynard et al. 2006). The mice in this study are all female which
allows the accumulations and/or deficiencies found to address specific mechanism failure to
the largest cohort of AD sufferers.

1.3 METAL DISTRIBUTION ASSOCIATED WITH AD
Basun et al. (1990) conducted a study comparing the concentration of metals in cerebrospinal fluid (CSF) and blood in patients with Alzheimer’s and healthy volunteers. Zinc and
Fe were only measured in blood and it was found that the Fe levels in the plasma of patients
with AD were decreased when compared to their controls. This could be studied in the brain
where deficiencies of Fe can be accounted to Fe-lacking plasma resulting in mechanism
failure. In the CSF component it was discovered that Cu had increased in patients with
Alzheimer’s when compared to their controls. This implicates metals as having direct links to
Alzheimer’s disease due to their concentrations, in the brain and outside the brain, increasing
or decreasing in patients with Alzheimer’s when compared to their healthy age-matched
controls.
Deibel et al. (1996), focused on the relationship between metals and Alzheimer’s disease
through analysing Cu, Fe and Zn levels in five different brain regions (amygdala,
hippocampus, inferior parietal lobule, superior and middle temporal gyri and cerebellum) in
samples from patients with AD and age-matched controls using instrumental neutron
activation analysis (INAA). Interestingly, a significant decrease in Cu concentrations was
notable in the hippocampus’ of patients with AD. Zinc and Fe were significantly increased in
the hippocampus of patients with AD which suggests the failure of a regulatory mechanism
for Zn and Fe. The decrease in Cu can represent a transporter mechanism failure for Cu
which could be resulting in accumulations elsewhere where the Cu isn’t being effectively
transported to the hippocampus. The cerebellum was described to be minimally affected in
AD and therefore no significant increase or decrease in metal levels was notable (Deibel et al.
1996). Zinc is suggested by this study to play a more major role in senile plaque formation
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than previously thought. This is supported by Kaden et al. (2011) where the role of Cu in AD
is hailed as a positive one where the metal is said to lower AB production in cell culture
systems through ‘promoting the non-amyloidogenic processing of APP’. Copper was
analysed as a treatment in this study where the decline of AB plaques in CSF was noted in
patients with AD treated with 8mg of Cu a day (Kaden et al. 2011). This further validates the
notion that accumulations of Cu, rather than being an effect of AD, are the cause of
detrimental metal mechanism failure not transporting Cu to the areas of the brain it needs to
be. Therefore, using bio-maps to study the metal distribution in transgenic mice brains would
be beneficial to further studies such as these.
The severity of AD can be linked with increased metal dyshomeostasis in the brain and metal
distributions can be studied to identify higher risk areas in a patient’s brain. Copper and Fe
levels in plaques were studied by Bourassa et al. (2013) to be elevated to a higher degree in
severe cases of AD. The study used three mouse models, two which showed
neurodegeneration and one with less severe neurodegeneration. Copper levels were found to
be increased by ~25% in the two models showing the higher degree of neurodegeneration
which implicates increased Cu levels corresponding with greater severity of AD. Iron levels
in the cortex were found to be increased as AD progressed in each of the three mouse models
(Bourassa et al. 2013). This can indicate that Cu plays a more integral role in severe cases of
AD than Fe and mapping the distribution of both metals will allow greater understanding of
areas at higher risk of neurodegeneration.

1.4 TREATMENTS FOR AD
1.4.1 Metal-based treatments for AD
Metal-based drug therapy or metal chelators have been explored through several journal
articles as a means of treating AD. Ayton et al. (2015) recognises the potential for treatments
directly targeting metals as a much more effective and time efficient solution. This introduces
the notion that if CBD is proven to regulate metal distribution in the brain, without adverse
effects on metal homeostasis, then it would both support its role as a treatment and further
explore the understanding of metals in relation to AD. Hung et al. (2010) have proposed that
treatment of the drug clioquinol to transgenic (Tg2576) mice expressing AD for 9 weeks
resulted in significantly lower plaque pathology and total amyloid-beta protein when
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compared to their controls. Accompanying the lower plaque pathology was a rise in the level
of Cu which was hypothesised by Hung et al. (2009) to implicate Cu as being deficient in
brains with AD. This direct link between Cu and AD could lead to alternative treatments
which target Cu in the brain and attempt to increase the amount of the metal in the brain so as
to return it to homeostasis. Therefore, the effect that treatment of CBD has on the amount and
distribution of metals in the brain when compared to untreated controls will contribute and
support the understanding between metals and their role in AD.

1.4.2 Cannabidiol treatment
The treatment of phytocannabinoid cannabidiol (CBD) as a therapeutic and preventative
treatment for AD was studied by Cheng et al. (2014). Cannabidiol belongs to the group of
molecules known as cannabinoids and is non-psychoactive and has proven in these studies to
exhibit neuroprotective, anti-oxidant and anti-inflammatory effects and promotes
neurogenesis. Cheng et al. (2014) found that chronic CBD treatment reversed cognitive
deficits in transgenic APPxPS1 mice with AD such as associated impairments in social
recognition and novel object recognition when being compared to healthy wild-type mice. It
is important to note that no anxiety was exhibited by the treated mice as a result of a negative
effect of the CBD. Another study by Cheng et al. (2014) exhibited CBD’s ability to prevent
the development of a social recognition deficit in transgenic mice with AD without any
impact on anxiety or associative learning. Therefore, the ability to treat and even prevent AD
with CBD needs to be effectively studied to validate the research already achieved to promote
its effectiveness. Metal distribution maps produced comparing the brains of transgenic mice
with AD and transgenic mice with AD treated with CBD will also be crucial in noting if CBD
has any effect on the distribution of metals in the brain.

1.5 LASER ABLATION ICP-MS AND BIO-IMAGING
The use of mapping in biomedical research is an increasingly popular and useful tool to
highlight and define areas of interest. Metal distribution maps are extremely useful to define
spatial trends of metals in biological samples. Bio imaging using laser ablation inductively
coupled plasma mass spectrometry (LA-ICP-MS) offers comprehensive maps of distributions
of metals in biological samples for various studies and is increasingly used in
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bioaccumulation and bioavailability studies in plants, humans and animals (Becker et al.
2014).
Laser ablation ICP-MS as a method has become more widely utilised over the last decade in
regards to bio-mapping metal distributions and was pioneered by Wang et al. (1994). The use
of this method to produce an accurate representation of metal distribution in the brain is much
more effective than the less specific bulk assay techniques previously utilised (Hare et al.
2015). In the LA ICP-MS method a laser beam is produced and focused onto the biological
sample to generate or ablate fine particles. These ablated particles are then transported via a
mix of carrier gases (can be a mix of He, N2 and/or Ar) to the inductively coupled plasma.
These particles experience extreme high temperatures in the plasma and subsequently convert
to ions. These ions are passed through the mass spectrometer where they are detected and
recorded as data into a csv file for further analysis. Matrix matched standards can be analysed
at the same time as the biological sample to provide internal quantification standards.
Imaging softwares such as Iolite and ImageEditor can then manipulate the data in the csv file
to produce a bio map of intensity (cps) which can then further be quantified into a map of
metal concentration (ppm). This method is extremely useful for accurately mapping metal
distribution in the brain due to its sensitive detection limit in the low µg g-1 range (Becker et
al. 2010). Becker et al. (2005) tested the ability of the LA ICP-MS method through using it to
to analyse sections of human brain hippocampus. Inhomogenous distribution of P, S, Cu and
Zn were analysed and the use of LA ICP-MS as a sensitive surface analytical technique was
found to be a success. The use of matrix matched laboratory standards in the analysis of the
hippocampal tissue was successfully used to quantify the elemental distribution in the region
(Becker et al. 2005). Jackson et al. (2006) analysed metal distribution in 100µ thick rat brains
and praised the ability of the LA ICP-MS method to collect multiple elements in a single
session and therefore speed up the process of analysis.
When compared to other methods such as secondary ion mass spectrometry (SIMS) and Xray fluorescence (XRF), LA ICP-MS stands out as being matrix insensitive and measures a
wide range of concentrations with an impressive and improving spatial resolution of down to
1µm (Becker et al, 2014). Hare et al. (2015) identifies that while the spatial resolution is
improving it has done so relatively slowly since the original 1994 study by Wang et al.
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Popescu et al. (2011) used X-ray fluorescence (XRF) to map and quantify metal distributions
in the brain and highly praised LA ICP-MS as a more effective and powerful method due to
its higher sensitivity
The methods used to mount biological samples on the slide as well as the LA ICP-MS
analytical method itself introduces large ranges of error where metals can be introduced or
lost throughout the process (Hare et al. 2015). Therefore, the internal standards and
calibrations in the LA ICP-MS method are extremely important to reduce the errors
introduced in the sample preparation and analytical process and yield accurate
quantifications. The calibration methods chosen are recognised by Hare et al. (2012) to be
quite dynamic as each experiment using this method can experience errors coming from a
multitude of sources. Thus, any single experiment using the LA ICP-MS method will need to
recognise and address each error it is encountering and account for it using its own
contextualised method of calibration and internal standards. Matrix-matched standards are
recognised by Hare et al. (2013) as the most effective means for producing accurate,
quantitative images using the LA ICP-MS method to produce metal distribution maps of
biological samples. The matrix-matched standards will contain known concentrations of trace
metals and through analysing these standards before and after a biological sample, a
calibration curve can be produced to transform the counts per second analysed in LA ICP-MS
to quantified concentrations of metals per pixel. Hare et al. (2013) tested how accurate these
calibration curves prove to be and repeated 8-point calibration curves that were ‘reproducibly
linear’ with correlation co-efficient ranging from ‘0.9874 (Mg) to 0.9991 (Sr)’ an example of
which is in Figure 4. This study has solidified the accuracy of the calibration curve method
and labelled the LA ICP-MS analysis as ‘suitable for quantifying most analytes in a sample
mouse brain’ (Figure 5).
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Figure 4 - An example of counts per second or ‘signal intensity’ normalised by C are created into a calibration curve
that can be used to quantify concentrations of trace metals in biological samples accurately (Hare et al. 2013)
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Figure 5 - The distribution of trace metals in the ‘C57BL/6 mouse brain at bregma −2.78 mm.’ (Hare et al. 2013)
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CHAPTER 2 – METHODOLOGY
2.1 SAMPLE PREPARATION
Thirty half (left side of sagittal section) female mice brains were received from Neuroscience
Research Australia (NeuRA) with 16 being wild-type (WT) (8 for control and 8 with CBD
treatment) and 14 being APPxPS1 AD affected (7 for control and 7 with CBD treatment) for
comparison. Each mouse was on average 12 months old and weighing 25g at the time of
sacrifice. Each brain was stored in a separate vial containing PFA and 30% sucrose for
effective cryoprotection before cryosectioning.
The vehicle solution used for the mice treated with cannabidiol consisted of powdered
cannabidiol (CAS: 13956-29-1 THC Pharma GmbH, Frankfurt/Main, Germany) which was
dissolved in equal amounts of Tween 80 (Sigma-Aldrich Co., St Louis, USA) and 100 %
ethanol to the appropriate concentration and was diluted with 0.9 % sodium chloride (Long et
al. 2010, 2012). Ethanol and Tween 80, a non-ionic detergent, comprised 10 % of the total
volume. The drugs were delivered via i.p. route.

2.2 CRYOSECTIONING PREPARATION
Each of the left side half mice brains were stored in separate vials at ~3°C until preparation
for cryosectioning. Four brains were prepared for cryosectioning at a time. Each brain would
undergo the exact same preparations to achieve consistency. Tweezers were used to retrieve
the brain out of the vial and the brain was laid immediately onto a paper towel to reduce
excess sucrose. The left sagittal side of the brain is then positioned with tweezers where the
flat and most central side of the brain is lying flat against a sample mould. OCT (freezing
agent) is then used to cover the brain and fill the mould so the OCT is flush with the surface
of the mould. Any bubbles resulting from this process are removed with tweezers. The
sample moulds containing the brains are then taken to a cryostat (Leica, CM1950) where the
chamber temperature is set to -15°C where the freezing agent will activate and completely
freeze the samples for cryosectioning.
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2.3 CRYOSECTIONING
The specimen holder temperature is set to -18°C, the width of cutting is set to 45µm and
process set to ‘sectioning’. Each sample is positioned and sectioned in the exact same method
to achieve consistency. Twelve blank gelatine coated slides are used for each sample with 4
sections on each slide amounting to 48 sections per sample. The sample to be sectioned is
oriented (Figure 6) and secured into the specimen holder to prevent slipping. The specimen
holder is oriented as accurately as possible using mechanical adjustments. This part of the
process has the potential to introduce quite a large error margin as the mechanical adjustment
is undertaken solely by the user and their judgement of how flush the blade is with the
sample. The limitations here are that a number of samples could have been cut at an angle to
the blade and are therefore not a true representative cross-section when imaged. As a section
is cut it will curl into itself unless a small paintbrush is used to keep it flat, therefore two
small paintbrushes are kept inside the chamber for the entire process so they remain at the
required temperature. The first sectioned cut is affixed onto the slide in the desired
orientation (Figure 6). In this case, 4 sections are required on each of the 12 slides (Figure 7).
Two initial slices are cut from the centre of the brain to remove excess OCT and enable
sectioning from the fresh sample. The first section cut is positioned on the top right corner of
Slide 1 and is the closest to the centre of the brain. The second section cut is positioned on the
top right corner of Slide 2 and this process is repeated until Slide 12. The thirteenth section is
positioned on Slide 1 on the top left corner, with the fourteenth being placed on the top left
corner of Slide 2. This is repeated up to Slide 12 until the twenty fifth section which is placed
on the bottom left corner of Slide 1. The twenty sixth section is placed on the bottom left
corner of Slide 2 and this is repeated up to Slide 12 until the thirty seventh section which is
placed on the bottom right corner of Slide 1. The thirty eighth section is positioned on the
bottom right corner of Slide 2 and is repeated until the forty eighth section is placed on the
bottom right corner of Slide 12. When each of the twelve slides have 4 sections affixed to
them then the mouse brain sample is finished with the top right section being closest to the
centre of the brain and the bottom left section being closest to the outer side of the brain
(Figure 7). Section 5 was used for analysis in this project. All of slides with fresh sample are
stored in a fume hood overnight to dry and then stored at room temperature until analysis.
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Figure 6 - The sagittal orientation of the sectioned slices is represented on the left and the regions of cerebellum and
olfactory bulb highlight on the right. The hippocampal region is located internally in the central region of the brain.
Images of the brain created using the software Brain Explorer 2 and then added to with drawing software.

Figure 7 – Demonstrating the position of each slice in regards to the mouse brain for one sample. Section 5 was
analysed in this project.
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2.4 LASER ABLATION ICP-MS
To measure metal concentration and distribution in each brain from the sectioned samples,
laser ablation inductively coupled plasma mass spectrometry (LA ICP-MS) was used. In LA
ICP-MS, a laser beam is produced and focused onto the biological sample to generate or
ablate fine particles. These ablated particles are then transported via a mix of carrier gases He
and N2 to the plasma torch. The sampled particles are excited in the plasma which causes
them to undergo ionisation and then a mass spectrometer can detect the excited ions for
analysis. In this study samples were ablated with a NWR193 ArF excimer laser ablation
system and analysed using a Thermo iCAP-Q single-collector ICPMS. In a single session, 4
samples were analysed with standards in-between each and a NIST, taking approximately 20
hours. The 5th section was chosen from each sample to preserve experiment viability by
reducing bias and enabling the comparison of sections from the same part of the brain. To
allow accurate quantification, matrix-matched lamb brain standards with known
concentrations are analysed before and after every sample to account for drift in plasma
conditions in an individual session. The sections B, C, D, E, F and G with known metal
concentrations were analysed using a maximum of 5 3mm merged lines through each
individual section (Bottom slide; Figure 7).
Each sample is set up with the exact same properties which were; laser spot size at 50µm, the
scan speed at 200µm/s, the repetition rate at 20Hz and fluence at 0.8 J/cm². The lines created
for the laser to follow are not merged to enable a comprehensive metal concentration map to
be created in the further software used. Qtegra software is used to set up the experiment to
run for the desired amount of time (calculated for each individual experiment using line
length and laser speed) and the analytes 63Cu, 13C, 31P, 59Co, 66Zn and 57Fe selected to be
collected. Helium is set at 650mL/s and turned on for approximately 10 minutes before the
experiment is run. Argon gas is turned on for approximately 20 minutes before each
experiment begins to purge the gas lines and eliminate any leftover remnants of previous
experiments analytes in the lines. Nitrogen can be turned on after this purge for
approximately 20 minutes before the experiment begins. In the experiment created in Qtegra
the acquisition parameters are set to ‘high’ resolution for analytes of interest (e.g. 63Cu, 66Zn
and 57Fe) and total dwell time set to 0.25 seconds (equal to spot size divided by scan speed)
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to reduce image distortion (Lear et al. 2012). The same rule applies to the dwell time as the
resolution where analytes of greater interest and abundance are given higher dwell times. The
dwell times for each isotope are as follows: 63Cu – 0.05 s, 13C – 0.03 s, 31P – 0.03 s, 59Co –
0.04 s, 66Zn – 0.05 s and 57Fe – 0.05 s. The washout time for the laser is set to 30 s and the
uptake time set to 15 s to give enough time for the laser to load before each line.
The laser emission is turned on and an auto-tune using NIST612 is undertaken before running
the experiment. NIST612 is a glass standard with known trace element concentrations used to
tune and calibrate the laser and ICP-MS. The NIST612 is analysed using a straight line
created running from the left side to the right side at an average 5mm length. The properties
on the NIST612 line are as follows: scan speed at 5 µm/s, fluence at 5 J/cm2, repetition rate at
5 Hz and spot size at 65 µm. The data is exported as a ‘Laser Data Reduction Export’ into a
folder as ‘csv’ files for analysis in imaging software.

2.5 IMAGING SOFTWARE AND DATA PROCESSING
Following collection, an imaging software is required to produce metal distribution maps, and
to convert isotope intensities (in counts per second) into metal concentrations (in ppm).
ImageEditor is efficient imaging software that proves to be easily navigable and was
therefore chosen to produce the metal concentration maps.
The data is imported into ImageEditor as “comma: time,intensity” as well as “continuous
data” to enable the software to turn 1 merged line of data from the laser into a
comprehensible map. To create an initial intensity map for a given isotope, the isotope of
interest is selected in the sidebar and the parameters set to velocity (200µm/s) and spot size
(50µm). The parameters of ‘split’ (ablation time per line plus time to move between lines and
change ‘DP’ to ‘s’) and ‘start x’ are unique to each sample. Rotation and reflection can be
manipulated to display the brain image in the orientation of choice. The initial product is a
map displaying intensity in counts per second (cps; Figure 8) and requires conversion into
concentration to produce a map of metal concentration.
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Figure 8 - An example of an initial map of laser counts per second for Cu for sample 234 created in ImageEditor. The
x and y axis represent a given sample’s coordinate position. Coloured scale represents laser counts per second for Cu.

The data acquired from the matrix-matched lamb brain standards can then be utilised to
create a calibration curve for each element (Cu, Zn and Fe) and quantify the sample that was
run between them. The standards are imported into ImageEditor as “comma: time,intensity”
and do not need to be imported as “continuous data” due to it being necessary to retrieve the
average from each of the 6 sections individually. Once imported the ‘select data’ tool in the
‘Data Selection’ tab can be utilised to select the data within each of the 5 lines for each of the
6 sections of the standard in relation to the isotope of interest (Figure 9). Once selected, this
data can be exported into Excel and the average of each of the six sections of standard
calculated.
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Figure 9 - An example of data from standards before selection for Cu for sample 234 in ImageEditor. The x and y
axis represent a given sample’s coordinate position. Coloured scale represents laser counts per second for Cu.

Using the average isotope intensities from the lamb brain standards against their known
element concentrations, a calibration curve is produced for the quantification of a particular
sample. Using the intercept and x-variable from each samples’ calibration curve, the maps of
intensity can be transformed into a metal concentration map using the ‘Quantifier’ tool in
ImageEditor (Figure 10). A decision was made to change the scale for all elements to a
maximum value of ‘25 ppm’ to allow better comparison of the metal concentration maps.
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Figure 10 - An example of a quantified image for Cu for sample 234 in ImageEditor

Normalisation to phosphorus (P) can also be implemented at this stage of data processing to
account for high readings. After experimentation, it was decided that the quantified metal
concentration map without normalisation to P was the most comprehensible and
representative map. The quantified image with normalisation to P is seen in Figure 11 as
detecting extremely low concentrations that were background metal levels and not relevant to
the metal distribution in the brain itself. The quantified image without normalisation to P is
seen in Figure 11 to be a much more representative map of metal distribution and when
compared to the map of intensity. Therefore, without using normalisation to P, a quantified
map for each samples’ Cu, Zn and Fe metal distribution was created totalling 90 maps. These
metal distribution maps were used to identify trends of accumulations and deficiencies
between Cu, Zn and Fe and further highlight key areas of interest.
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Figure 11 - An example of a quantified map of Cu ppm normalised to P, a quantified map of Cu ppm and an intensity
map of 63Cu for sample 296 created in ImageEditor. The x and y axis represent the position of the given sample.

2.6 SPATIAL ANALYSIS
To extract the data values from regions of interest, such as the hippocampus and cerebellum,
as well as extract total average concentrations, a method was devised using ArcGIS software
(ESRI, ArcMap 10.2). ArcGIS was chosen due to the ease of the software to be utilised to
select regions and extract data from them. The creation of a base brain map is necessary to
effectively georeference each sample (Figure 12). The base brain map is given a scale and
control points to produce a georeferenced image using the georeferencing tool. From this
base brain map, each sample’s metal concentration maps can be accurately referenced to
scale.
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Figure 12 - An example of the brain map chosen to act as a base when referencing the bio maps in ArcGIS. Source:
Allen Institute for Brain Science (2017)

The data from each metal distribution map created in ImageEditor was exported as a ‘csv’
file and uploaded into ArcCatalog for manipulation using ArcGIS. Each Cu, Zn or Fe, file is
converted into a shapefile from its XYZ table and then further converted into a raster dataset.
These rasters can then be manipulated using the georeferencing tool and effectively ‘pinned’
down using control points onto the base brain map so that an individual samples area of
interest of the brain, such as the hippocampus, can be aligned accurately with the base brain
map (Figure 13). Due to the nature of the sample brains not always fitting perfectly over the
base brain, each brain was referenced individually and has individual control points and
might sit slightly differently over the base brain. The control points use a 1st order polynomial
(affine) transformation and a least square fitting (LSF) algorithm to permanently match the
control points to their new position. This least square fitting method determines a line of best
fit where each ‘square’ is created using a mathematical function that squares the distance
between a data point and the regression line. After each sample’s Cu, Zn and Fe metal
distribution maps are referenced as close as possible to the base brain map it is now possible
to create a polygon to overlay a region of interest and extract values from it.
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Figure 13 - An example of a referenced Cu concentration raster dataset for sample 298 in ArcGIS showing its control
points from the georeferencing tool. The numbers correlate with each control point created to ‘pin’ it down to the
base brain map.

To extract data from specific areas of the brain, a new feature class is created as a polygon
feature and used to outline the area of interest. This polygon directly overlies the area of
interest when used with each individual sample and its corresponding metal concentration
maps (Figure 14). Due to only one base polygon being used to overlay it, it is extremely
important that each sample is referenced as close as possible to the area of interest, which
means that other areas of the brain can warp. This step introduces a large margin of error due
to only using one base polygon to overlay every Cu, Fe and Zn concentration maps when
each individual sample can differ slightly. Due to the nature of a brain, it is impossible to
perfectly align every sample so the error introduced in this step is necessary to give an
indication of an as accurate as possible average concentration of regions in the brain. To
extract the concentrations of the area of interest, the tool ‘extract values to a table’ is utilised
with a polygon feature class for the selected area (e.g. hippocampus) and the raster dataset of
an individual sample. From this data, the average concentration for the area of interest can be
exported as a table into Excel and the average concentrations of the area of interest (e.g.
hippocampal region) calculated.
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Figure 14 - An example of a referenced Cu image for sample 298 and its hippocampal region polygon overlaying it in
ArcGIS

The initial average concentration values achieved using the ‘extract values to a table tool’ in
ArcGIS had unusually small amounts of data points. After cross-referencing the classified
colour scheme and corresponding value in ArcGIS for the hippocampal region with the data
output from the tool it became apparent that the tool was not picking up on every data point.
This was found to be due to the conversion of the data from a shapefile to a raster overcomplicating the process and causing the tool to extract only limited data points. Therefore,
the data needed to be extracted from its original shapefile and a different tool utilised.
The georeferenced raster image and base brain reference were employed again as a means of
positioning the shapefile the correct way to extract from the nominated region accurately. To
interpret the shapefile as the brain map, it was necessary to re-symbolise the image as
‘quantities’ in relation to its ‘I’ value (intensity values). The ‘spatial adjustment tool’ was
utilised to employ displacement tool links to reference the shapefile to the already referenced
raster layer file. The polygon required for the area of interest then allowed selection of every
data point within the polygon when overlain on the shapefile through the ‘selection’ tool
(Figure 15). The selected data points could then be copied into an Excel sheet and accurate
average concentrations calculated. The data extracted from ArcGIS was still in its intensity
(cps) form and therefore each average needed to be further converted into concentration
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(ppm) using the calibration curve produced previously for each samples’ Cu, Zn and Fe map
respectively. This was repeated until every sample had an average concentration for the areas
of hippocampus, cerebellum and whole brain for Cu, Zn and Fe.

Figure 15 - An example of the referenced Cu shapefile and its selected region from the cerebellum polygon using the
selection tool in ArcGIS
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CHAPTER 3 – RESULTS AND DISCUSSION
3.1 COPPER
3.1.1 Copper in the whole brain
Copper levels are known to be increased in areas of enhanced plaque pathology and therefore
play a fundamental role in AD processes in the brain (Greenough et al. 2013). The Cu
concentration in each sample’s whole brain was analysed to compare trends between the
groups. Regions identified with increased Cu concentration can indicate regions of enhanced
plaque pathology and AD processes.
Average Cu concentrations for the whole brain were calculated for each of the 30 brains
(Appendix 1). Following these calculations, the average value for each of the four groups was
achieved (Table 1). Copper had an average concentration of 3.12 ± 0.95 ppm (2 STD. ERR.;
n = 7) in an AD brain and 3.73 ± 1.42 ppm (2 STD. ERR.; n = 8) in a WT brain (Table 1). Cu
concentrations in the whole brain of AD mice were higher 3.75 ± 0.79 ppm (2 STD. ERR.; n
=7) when treated with CBD and increased in WT mice to 5.07 ± 1.99 ppm (2 STD. ERR.; n =
8) when treated. The p values of each comparative group were calculated using an unpaired t
test to compare the averages of one group against another which yielded no significant results
apart from the comparative group of AD vs WT CBD (Table 2). The p value for this
comparative group is indicative of a potential Cu deficiency in AD brains when compared to
increased Cu concentrations in healthy, WT brains treated with CBD. An increase or decrease
in Cu can be a direct result of regulatory mechanism failure such as in the case of the metal
binding protein ‘metallothionein’ which binds with Cu to reduce the amount of detrimental
free radicals in the brain (Freedman et al. 1989).
Table 1 - Average Cu concentrations in whole brain for each group

Group

Mean (Cu ppm)

Standard Deviation

Standard Error

n

AD

3.12

0.95

0.36

7

WT

3.73

1.42

0.50

8

AD_CBD

3.75

0.79

0.30

7

WT_CBD

5.07

1.99

0.70

8

Standard Deviation – population standard deviation (measure of uncertainty in regards to every sample in a given group);
standard error of the mean - estimates variability between sample

29

Table 2 - The t test generated p value for each comparative group’s (vs) average Cu concentration in the whole brain

Group (vs)

p-value

AD vs WT

0.35

AD_CBD vs AD

0.20

AD_CBD vs WT_CBD

0.13

WT_CBD vs WT

0.14

WT vs AD_CBD

0.97

AD vs WT_CBD

0.04

Copper concentrations in the whole brain across the 4 groups are shown to be deficient in the
corpus callosum (Figure 16 and Figure 17; Appendix 4). The corpus callosum is the region of
the brain that connects the two hemispheres and deficiency of Cu in this region can indicate
the failure of Cu transporters in the brain. Transportation failure is seen more frequently in
brains affected with AD such as the deficiency of the Cu transporting protein ceruloplasmin
(Snaedel et al.1998). Apart from this one overarching trend between the groups, it is quite
difficult to identify trends occurring in a particular group that differentiate it from the rest.
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Figure 16 - The Cu concentration (coloured scale; in ppm) for the first three samples analysed in each group. The x and y axis represent a given sample’s coordinate position. AD
represents untreated APPxPS1 mice ad AD CBD represents APPxPS1 mice treated with cannabidiol (CBD). WT represents untreated wild type, healthy mice and WT CBD
represents wild type, healthy mice treated with CBD.
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Figure 17 - The distribution of Cu concentration (coloured scale; in ppm) for Sample 274 showing Cu deficiency in
the corpus callosum (located approximately centrally in the square). The x and y axis represent coordinate position of
the sample.

Copper concentrations in the whole brain are lower in AD mice (Figure 16). The lower
average Cu concentration in the brain for mice with AD explores the idea that Cu is deficient
in an AD brain when compared to healthy, WT mice brains. The therapeutic role of metal
chelators and treatments targeting more effective transportation and production of metals
such as Cu could be studied to prove more effective when targeting and treating AD (Ayton
et al. 2015). Kaden et al. (2011) found a decline in amyloid-beta (AB) plaques when treating
transgenic mice with AD with Cu which further builds upon the idea that Cu could be used to
promote wider metal distribution and metal homeostasis in an AD brain. Therefore, Cu could
provide a therapeutic role in its interaction with AD processes. The decreased mitochondrial
activity in a brain with AD leading to Cu and Zn accumulations noted in Duce et al. (2010)
can also explain the lower average Cu concentration found in the AD brains. The
accumulations of Cu and Zn in the glutamatergic synapse were caused by transporter
mechanisms failing to distribute them around the brain which could result in an overall
average lower concentration of the metals. This can explain the increased Cu concentration in
the rims of plaques in patients with AD studied by Lovell et al. (1998) whilst also supporting
the lower average Cu concentration in AD brains found in this study. The correlation of
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increased Cu concentration and increased severity of AD studied in Bourassa et al. (2013)
could also play a role in understanding the lower average Cu concentration in the AD mice.
The severity of AD in the mice analysed in this study might not have reached the stage where
Cu begins to increase. This is an interesting avenue for future studies to approach by
comparing the metal distribution in the brains of AD and WT mice at different stages of AD.

AD

WT

AD CBD

WT CBD

Figure 18 - Average Cu concentrations (ppm) in whole brain for each group

Interestingly, CBD treatment results in an increase in the median Cu concentration in both
AD and WT brains (Figure 18). CBD could be promoting higher Cu concentrations in the
brain. Hung et al. (2009) found that increased Cu levels correlated with lower plaque
pathology when treating AD brains with clioquinol therefore it is necessary to analyse plaque
pathology in relation to CBD treatment to further support this idea. It is also interesting to
note that treated and untreated AD brains had lower standard deviations when compared to
treated and untreated WT brains (Table 1). This suggests that WT brains have a greater
variability in average Cu concentration. Although the high variability seen in WT directly
contrasts with the idea that healthy brains have an improved metal homeostasis. This is since
metal homeostasis should translate to low standard deviation due to the more effectively
regulated metal concentration. Therefore, the variability in Cu concentration in WT brains in
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this study could be due to errors influencing the results, such as metal contamination in the
analytical process. The significant difference between the group of AD when compared to
WT CBD using the unpaired t test further supports that metal levels in a healthy brain
increase when treated with CBD. This is due to the trend of AD mice having a lower average
concentration of Cu in the brain when compared to WT, healthy mice. Therefore, the
deficient, AD brain, would be expected to be significantly different to a brain with increased
Cu concentrations, such as is seen when WT mice are treated with CBD.
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3.1.2 Copper in the hippocampus
The hippocampus is a region in the brain responsible for learning, memory and emotions and
is directly affected in AD (Greenough et al. 2013). Enhanced plaque pathology is noted in the
hippocampal region which raises interest in regards to the metal distribution also noted in the
area. The trends in Cu concentration identified in the analysis will therefore be discussed to
identify regions of interest for AD processes and in relation to CBD treatment. Average Cu
concentrations for the hippocampus were calculated for each of the 30 brains (Appendix 1).
Following these calculations, the average value for each of the four groups was achieved
(Table 3). The average Cu concentration in the hippocampus for AD brains 6.39 ± 3.20 ppm
(2 STD. ERR.; n = 7) was lower than the average for WT 8.65 ± 3.93 ppm (2 STD. ERR.; n =
8). This supports the study by Deibel et al. (1996) that found Cu to be significantly decreased
in the hippocampus of AD patients.
Table 3 - Average Cu concentrations in hippocampus for each group

Group

Mean (Cu ppm)

Standard Deviation

Standard Error

n

AD

6.39

3.20

1.21

7

WT

8.65

3.93

1.39

8

AD_CBD

5.72

1.87

0.71

7

WT_CBD

11.11

8.63

3.05

8

Standard Deviation – population standard deviation (measure of uncertainty in regards to every sample in a given group);
standard error of the mean - estimates variability between sample

The difference between the average concentrations seen in AD and WT in the hippocampus,
although not statistically significant (Table 4), is further supporting the idea that Cu is
deficient in an AD brain. The decreased average Cu concentration in the hippocampus can
also be interpreted as transporter failure, which is also seen in the deficiency of the Cu
transporting protein ceruloplasmin studied in AD patients (Snaedel et al. 1998). The failure of
these transporter mechanisms could be resulting in Cu not being transported effectively to the
hippocampus and accumulating elsewhere. Where exactly this Cu is accumulating is not
abundantly clear in the AD brains when compared to the WT groups (Figure 16; Appendix
4). Future studies can further explore Cu accumulations outside of the hippocampus to paint a
clearer picture of where the transporter mechanisms begin failing. The brain of a patient with
AD is studied in Ayton et al. (2013) to suffer from metallostasis which refers to the
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interruption of metal trafficking mechanisms. Metallostasis is implicated in this study to
result in the redistribution of metals, specifically Cu, Zn and Fe, into sporadic areas of the
brain which disrupts metal ion homeostasis. The lower average Cu concentration in the
hippocampus in AD brains when compared to WT brains analysed in this study could be a
direct result of the metallostasis in the AD brain.
Table 4 - The t test generated p value for each comparative group’s (vs) average Cu concentration in the
hippocampus

Group (vs)

p-value

AD vs WT

0.25

AD_CBD vs AD

0.67

AD_CBD vs WT_CBD

0.13

WT_CBD vs WT

0.48

WT vs AD_CBD

0.096

AD vs WT_CBD

0.20

The average variability of Cu concentration in the hippocampus for each group is studied to
be more variable than the variability studied in the entire brain for each group (Table 3). This
is interesting as it indicates that the Cu concentrations in each hippocampal region are highly
variable which highlights a hotspot for metal mechanism function. This could be the result of
each individual brain experiencing a different mechanism failure therefore the distribution of
metals is caused to be extremely variable. This could also indicate that for a given brain, the
average Cu concentration is relatively invariable unless you are focusing on specific regions,
such as the hippocampus. Therefore, the distribution of Cu is seemingly regulated more
efficiently; this could be due to the regulatory processes such as is seen when metals pass
through the blood brain barrier (Duce et al. 2010).
Cannabidiol treatment results in no statistically significant changes in the Cu concentrations
in both AD and WT brains (Table 4). However, as a general trend, CBD treatment increases
average Cu concentration in the hippocampus in WT brains from 8.65 ± 3.93 ppm (2 STD.
ERR.; n = 8) (untreated) to 11.11 ± 8.63 ppm (2 STD. ERR.; n = 8) (treated). The increase in
Cu concentration in brains treated with CBD when compared to untreated brains, while not
statistically significant, is also seen in the whole brain analysis (Figure 19). Therefore, the
trend for Cu concentration to increase in WT brains when treated with CBD is seen, not just
36

generally over the whole brain, but in specific regions such as the hippocampus. This trend
could be pointing towards CBD treatment as therapeutic in the context of metal-based
treatment studies across the whole brain as well as its specific compartments (Ayton et al.
2015). Alternatively, CBD treatment could be proven to be toxic in the long-term in regards
to its ability to increase the Cu concentration in otherwise healthy brains. This is seen in the
increase of Cu concentration in WT brains when treated with CBD as disrupting the metal
homeostasis that should be evident in healthy brains.

AD

WT

AD CBD

WT CBD

Figure 19 - Average Cu concentrations (ppm) in the hippocampus for each group
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3.1.3 Copper in the cerebellum
The cerebellum is known to display concentrated plaque pathology and is one of the regions
in the brain directly affected in AD (Hardy, J. and D. J. Selkoe, 2002). Therefore, copper
distribution in the cerebellum should identify areas of enhanced plaque pathology when it is
accumulated. The analysed Cu distribution and subsequent average concentrations will be
discussed in regards to AD processes. The cerebellum is identified to have sporadic degrees
of enrichment across every brain in every group (Figure 16; Appendix 4). Cu deficiency in
white matter and Cu enrichment in grey matter is noticeable in every brain in every group
(Figure 16). The clear difference between Cu concentration in white and grey matter will be a
useful tool when targeting mechanisms that need Cu to function in these regions of the
cerebellum. Average Cu concentrations for the cerebellum were calculated for each of the 30
brains (Appendix 1). Following these calculations, the average value for each of the four
groups was achieved (Table 5). The average Cu concentration in the cerebellum of brains
with AD was lower than the average concentration in WT brains (Figure 20). Therefore, for
the whole brain, hippocampus and cerebellum it is evident that on average the Cu
concentrations in a brain with AD are slightly lower when compared to WT brains.
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Figure 20 - Average Cu concentrations (ppm) in the cerebellum for each group

Table 5 - Average Cu concentrations in the cerebellum for each group

Group

Mean (Cu ppm)

Standard Deviation

Standard Error

n

AD

4.40

1.08

0.41

7

WT

5.82

1.72

0.61

8

AD_CBD

5.50

1.91

0.72

7

WT_CBD

6.96

2.81

0.99

8

Standard Deviation – population standard deviation (measure of uncertainty in regards to every sample in a given group);
standard error of the mean - estimates variability between sample

The cerebellum has a notably more significant p value between the two groups of AD and
WT mice when compared to the whole brain and hippocampus Cu concentrations with a p
value of 0.08 (Table 6). The lower Cu concentration in the cerebellum of AD brains can again
be pointing towards an overall deficiency of Cu in the brains of patients with AD. This can
suggest that metal specific treatments, such as metal chelators, would be a more efficient
means of treating the disease (Hung et al. 2009).
Cannabidiol treatment is again seen to increase the average Cu concentration in the
cerebellum of both AD and WT brains. This could be indicative of the CBD treatment having
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a therapeutic effect on an AD brain by raising its Cu concentration. Contrastingly, it could be
leading to a toxic effect on a WT brain by unbalancing metal homeostasis in regards to Cu. It
is important to note that the average concentrations analysed for Cu in the cerebellum had the
smallest standard deviations which suggests that Cu concentrations are less variable in the
cerebellum. This could suggest that the cerebellum is more tightly regulated than the
hippocampus and can therefore control its metal content more efficiently.
Table 6 - The t test generated p value for each comparative group’s (vs) average Cu concentration in the cerebellum

Group (vs)

p-value

AD vs WT

0.08

AD_CBD vs AD

0.21

AD_CBD vs WT_CBD

0.27

WT_CBD vs WT

0.34

WT vs AD_CBD

0.74

AD vs WT_CBD

0.04
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3.2 ZINC
3.2.1 Zinc in the whole brain
Zinc is implicated in the formation of AB plaques and predicted to have a significantly
increased average concentration in the AD mice brains compared to WT brains correlating
with enhanced plaque pathology. In direct contrast to Cu, it is evident in the Zn whole brain
metal distribution maps that the corpus callosum has an enriched Zn concentration across all
samples (Figure 21 and Figure 22; Appendix 5). This enrichment of Zn in the corpus
callosum is useful for future studies when looking at mechanisms in the brain requiring Zn.
Zn is highly enriched in this region and therefore dictates a region where Zn is not being
taken up by mechanisms resulting in accumulation (Duce et al. 2010). Alternatively, the Zn
enrichment of the corpus callosum region can indicate the high function of Zn transporter
mechanisms. If it is representing effective Zn transporter function it could implicate Cu
transporter mechanism failure in regards to Cu deficiency in the area (Figure 17 and Figure
22).
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Figure 21 - The Zn concentration (coloured scale; in ppm) for the first three samples analysed in each group. The x and y axis represent a given sample’s coordinate position. AD
represents untreated APPxPS1 mice ad AD CBD represents APPxPS1 mice treated with cannabidiol (CBD). WT represents untreated wild type, healthy mice and WT CBD
represents wild type, healthy mice treated with CBD.
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Figure 22 - The distribution of Zn concentration (coloured scale; in ppm) for Sample 274 showing Zn enrichment in
the corpus callosum (located approximately centrally in the square). The x and y axis represent coordinate position of
the sample.

Average Zn concentrations for the whole brain were calculated for each of the 30 brains
(Appendix 3). Following these calculations, the average value for each of the four groups was
achieved (Table 7). The Zn concentration in an AD brain is 2.29 ± 3.19 ppm (2 STD. ERR.;
n= 7) which is 0.70 ppm lower than the average concentration of Zn in WT mice brains
(Table 7). Large variability is evident in the Zn concentrations across all brains which is
further supported by the lack of statistically significant p values for each comparative group
(Table 8). This variability can be linked with the extremely low Zn concentrations analysed
in the brains resulting in 11 brains giving an average concentration for the whole brain of 0
ppm (Figure 23). This value of 0 ppm is defined as being below the detection limit of 0.085
ppm. This could be a result of analytical error where metal levels were lost in sample
preparation processes. Alternatively, Zn concentrations across the whole brain might be too
low for a definitive average and could prove to be more effectively analysed within specific
regions. Definitive Zn concentrations across the whole brain could be achieved through a
larger sample size in future studies which will reduce the influence of the zero values in the
data.
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Figure 23 - Average Zn concentrations (ppm) in whole brain for each group

Table 7 - Average Zn concentrations in the whole brain for each group

Group

Mean (Zn ppm)

Standard Deviation

Standard Error

n

AD

2.29

3.19

1.21

7

WT

2.99

3.74

1.32

8

AD_CBD

4.87

5.23

1.98

7

WT_CBD

5.13

6.44

2.28

8

Standard Deviation – population standard deviation (measure of uncertainty in regards to every sample in a given group);
standard error of the mean - estimates variability between sample
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Table 8 - The t test generated p value for each comparative group’s (vs) average Zn concentration in the whole brain

Group (vs)

p-value

AD vs WT

0.71

AD_CBD vs AD

0.28

AD_CBD vs WT_CBD

0.93

WT_CBD vs WT

0.43

WT vs AD_CBD

0.43

AD vs WT_CBD

0.31

It is important to note that CBD treatment for both AD and WT brains increased the average
Zn concentration for each samples’ whole brain. Cannabidiol treatment increased Zn
concentration in an AD brain from 2.29 ± 3.19 ppm (2 STD. ERR.; n = 7) to 4.87 ± 5.23 ppm
(2 STD. ERR.; n=7) and from 2.99 ± 3.74 ppm (2 STD. ERR.; n= 8) to 5.13 ± 6.44 ppm (2
STD. ERR.; n=8) in WT brains. Higher Zn concentrations are implicated with enhanced
plaque pathology and therefore the promotion of an increased Zn concentration when a
healthy brain is treated with CBD could prove to be toxic (Tiiman et al. 2013). Essentially,
the CBD treatment is ‘turning’ the average metal concentration in an otherwise healthy WT
brain into a brain exhibiting metal concentration levels associated with AD. This could be
further explored in future studies by larger sample groups of CBD treated mice and the
analysis of metal-related toxicity when compared to controls.
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3.2.2 Zinc in the hippocampus
The hippocampus is an important region of the brain when studying AD due to its normal
function being directly affected in the disease. Higher Zn concentrations are seen in areas of
the brain with increased plaque pathology, such as the hippocampus, and it is therefore
necessary to analyse the distribution of Zn in this region. Average Zn concentrations for the
hippocampus were calculated for each of the 30 brains (Appendix 3). Following these
calculations, the average value for each of the four groups was achieved (Table 9).
Table 9 - Average Zn concentrations in the hippocampus for each group

Group

Mean (Zn ppm)

Standard Deviation

Standard Error

n

AD

2.29

3.66

1.38

7

WT

3.97

4.06

1.44

8

AD_CBD

6.26

7.29

2.76

7

WT_CBD

4.47

5.07

1.79

8

Standard Deviation – population standard deviation (measure of uncertainty in regards to every sample in a given group);
standard error of the mean - estimates variability between sample

Zinc had low, almost undetectable levels in the whole brain resulting in values of 0ppm for
the average concentration across the brain. This value of 0ppm is defined as being below the
detection limit of 0.085ppm. This is again seen in the average Zn concentration in the
hippocampus where the 0ppm values greatly influence the data extracted from ArcGIS,
specifically the median (Figure 24). The inclusion of 0ppm values in the calculation of the
average concentration for Zn in the hippocampus (Table 10) was compared to the p values
generated when not including the 0ppm values (Table 11). The p values remained statistically
insignificant across all comparative groups (Table 11) and the average Zn concentration in
every group increased from the average concentrations including 0ppm by ~2ppm. Analysing
the data without the values of 0ppm did not lead to any new emerging trends and the
deductions taken from the values remained the same. Therefore, it was decided to examine
the data with the inclusion of the values of 0ppm for average Zn concentrations across each
group.
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Figure 24 - Average Zn concentrations (ppm) in hippocampus for each group

Table 10 - The t test generated p value for each comparative group’s (vs) average Zn concentration in the
hippocampus

Group (vs)

p-value

AD vs WT

0.42

AD_CBD vs AD

0.22

AD_CBD vs WT_CBD

0.59

WT_CBD vs WT

0.83

WT vs AD_CBD

0.46

AD vs WT_CBD

0.36
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Table 11 - The t test generated p value for each comparative group’s (vs) average Zn concentration in the
hippocampus (not including values of 0 ppm)

Group (vs)

p-value

AD vs WT

0.70

AD_CBD vs AD

0.49

AD_CBD vs WT_CBD

0.69

WT_CBD vs WT

0.75

WT vs AD_CBD

0.53

AD vs WT_CBD

0.59

The highest levels of Zn were analysed to be found in the hippocampus when analysing
“normal” values for the brain (Ramos et al. 2014). Contrastingly, the average Zn
concentration in the hippocampus of AD mice brains was slightly lower than the average
concentration in WT brains. This directly conflicts with the study by Deibel et al. (1996)
which found Zn to be significantly increased in the hippocampus of AD patients. This
conflict could be due to the different method of instrumental neutron activation analysis
(INAA) being utilised by Deibel et al. 1996 being more sensitive to Zn. The decrease in Zn
concentration in the hippocampus could also be explained by the metallostasis found in AD
patients studied by Ayton et al. 2013. The metallostasis evident in AD brains could be
leading to the redistribution of Zn to other compartments of the brain. The variability of
average Zn concentration in the hippocampus across all brains (Figure 21; Appendix 5) could
also be explained by metallostasis in brains with AD. The redistribution of metals could lead
to accumulations in any part of the brain, leading to no clear trend between groups. Future
studies can further analyse why Zn concentrations are so variable in the hippocampus through
further comparison with a larger sample size. The failure of transporter mechanisms to
distribute Zn around the brain evident in AD could also be contributing to the lower average
Zn concentration in the hippocampus of AD mice. The ability of the APP to absorb Zn and
reduce metal accumulation in a healthy brain as studied by Duce et al. 2010 is diminished in
an AD brain and leads to Zn accumulation. This could directly affect the Zn transporters
ability to transport the metal effectively and could lead to deficient concentrations of Zn in
the hippocampus.
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Cannabidiol treatment to both AD and WT mice is seen to raise the average concentration of
Zn in the hippocampus (Figure 24). However, the standard deviation and general variability
of the average concentration for each brain treated with CBD was extremely high which is
even visually evident in Figure 21. Therefore, further analysis with larger sample sizes is
necessary to draw conclusions on the effect CBD treatment has on Zn concentration in the
hippocampus.

3.2.3 Zinc in the cerebellum
The Zn concentration in the cerebellum is identified to directly contrast with white and grey
matter enrichment/deficiency evident in the cerebellum for Cu (Figure 16 and Figure 21;
Appendix 5). The enrichment of Cu in the cerebellum grey matter is correlated with a
deficiency in Zn. Zinc is then enriched in cerebellum white matter which correlates with Cu
deficiency in cerebellum white matter. This provides a useful tool for future studies when
analysing mechanisms involved with metal distribution in the cerebellum.
Average Zn concentrations for the cerebellum were calculated for each of the 30 brains
(Appendix 3). Following these calculations, the average value for each of the four groups was
achieved (Table 12). The average of Zn concentration in the cerebellum of mice with AD
when compared with the brains of WT mice is not significantly different (Table 13). A very
slight decrease in average Zn concentration in AD brains 2.75 ± 3.04 ppm (2 STD. ERR.;
n=7) is evident when compared with WT concentrations 3.33 ± 3.55 ppm (2 STD. ERR.;
n=8). This is supported by Deibel et al. (1996) which studied no significant increase or
decrease in metal levels in the cerebellum. This can again be supported by the lower standard
deviation values evident across each group for the cerebellum region conveying tighter metal
regulatory function (Figure 25).
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Figure 25 - Average Zn concentrations (ppm) in the cerebellum for each group

Table 12 - Average Zn concentrations in the cerebellum for each group

Group

Mean (Zn ppm)

Standard Deviation

Standard Error

n

AD

2.75

3.04

1.15

7

WT

3.33

3.55

1.26

8

AD_CBD

5.45

5.72

2.16

7

WT_CBD

4.57

4.39

1.55

8

Standard Deviation – population standard deviation (measure of uncertainty in regards to every sample in a given group);
standard error of the mean - estimates variability between sample
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Table 13 - The t test generated p value for each comparative group’s (vs) average Zn concentration in the
hippocampus

Group (vs)

p-value

AD vs WT

0.74

AD_CBD vs AD

0.29

AD_CBD vs WT_CBD

0.74

WT_CBD vs WT

0.54

WT vs AD_CBD

0.40

AD vs WT_CBD

0.37

A slight increase in Zn concentration in the cerebellum of CBD treated brains when
compared to untreated brains is also evident (Figure 25). This increase is not statistically
significant and paired with high variability between every brain unindicated by group (Table
13). Future studies can further analyse this trend of increase Zn concentration in treated AD
and WT cerebellums with necessity for a larger sample size.
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3.3 IRON
3.3.1 Iron in the whole brain
Iron is also implicated in enhanced plaque pathology due to increased concentrations of the
element analysed in such regions, such as the hippocampus and cerebellum. The analysis of
Fe distribution across the brain is necessary to indicate regions with advanced plaque
pathology in AD brains when compared to WT brains. The Fe distribution across the brains
sampled in this study will be discussed in the context of AD processes as well as metal
distribution trends post-CBD treatment. Average Fe concentrations for the whole brain were
calculated for each of the 30 brains (Appendix 2). Following these calculations, the average
value for each of the four groups was achieved (Table 14).
Iron is identified to be enriched in the cerebellum and olfactory bulb across every samples’
metal concentration map (Figure 26; Appendix 6). It is apparent that the average Fe
distribution across the 30 brains does not present a trend defining one group exclusively
(Figure 26). This is supported for the whole brain where the average Fe concentration
between AD mice and WT mice differs by the insignificant amount of 0.11ppm (Table 14).
This suggests that the average Fe concentration in the whole brain does not significantly
differ between AD and WT (Table 15). The average Fe concentration could significantly
differ between specific regions, such as the hippocampus and cerebellum, which will be
discussed further.
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Figure 26 - The Fe concentration (coloured scale; in ppm) for the first three samples analysed in each group. The x and y axis represent a given sample’s coordinate position. AD
represents untreated APPxPS1 mice ad AD CBD represents APPxPS1 mice treated with cannabidiol (CBD). WT represents untreated wild type, healthy mice and WT CBD
represents wild type, healthy mice treated with CBD.
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Table 14 - Average Fe concentrations in the whole brain for each group

Group

Mean (Fe ppm)

Standard Deviation

Standard Error

n

AD

2.15

2.44

0.92

7

WT

2.04

3.01

1.06

8

AD_CBD

2.52

2.31

0.87

7

WT_CBD

4.18

3.13

1.11

8

Standard Deviation – population standard deviation (measure of uncertainty in regards to every sample in a given group);
standard error of the mean - estimates variability between sample

Table 15 - The t test generated p value for each comparative group’s (vs) average Fe concentration in the whole brain

Group (vs)

p-value

AD vs WT

0.94

AD_CBD vs AD

0.78

AD_CBD vs WT_CBD

0.27

WT_CBD vs WT

0.19

WT vs AD_CBD

0.74

AD vs WT_CBD

0.19

Treatment of CBD is analysed to increase the average Fe concentrations in the whole brain
for both AD and WT (Figure 27). The average Fe concentration for untreated AD brains is
analysed to be 2.15 ± 2.44 ppm (2 STD. ERR.; n=7) and increases to 2.52 ± 2.31 (2 STD.
ERR.; n=7) when treated with CBD. This is a relatively insignificant increase but supports
the general trend that CBD treatment will increase the Fe concentration in an AD brain. The
average Fe concentration for untreated WT brains is analysed to be 2.04 ± 3.01 (2 STD.
ERR.; n=8) which doubles to 4.18 ± 3.13 (2 STD. ERR.; n=8) when treated with CBD. This
suggests a more significant increase in Fe concentration when otherwise healthy brains are
treated with CBD. Therefore, for each metal intrinsically linked to AD (Cu, Fe, Zn), CBD
results in an increase in average concentration. As discussed previously this could point to a
beneficial therapeutic treatment resulting in higher concentrations of metals leading to metal
homeostasis in a metal deficient AD brain or a toxic increase in healthier, more stable brains.
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Figure 27 - Average Fe concentrations (ppm) in whole brain for each group
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3.3.2 Iron in the hippocampus
It is necessary to analyse the distribution of Fe in the hippocampus in the context of AD
processes due to the correlation of increased Fe concentration being evident in areas of
increased plaque pathology in AD such as the hippocampus (Greenough et al. 2013). Iron is
enriched in the hippocampal region across every sample (Figure 26; Appendix 6). Iron is also
seen to have been the most affected by contamination with most samples being dotted with
uncharacteristic and variable high concentrations. This could represent that Fe is more easily
introduced in the analytical process and therefore future studies will need to address this to
produce less contaminated results for Fe. These areas of contamination can be influencing the
average concentrations and representative data (Figure 28). Average Fe concentrations for the
hippocampus were calculated for each of the 30 brains (Appendix 2). Following these
calculations, the average value for each of the four groups was achieved (Table 16).

AD

WT

AD CBD

WT CBD

Figure 28 - Average Fe concentrations (ppm) in the hippocampus for each group
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Table 16 - Average Fe concentrations in the hippocampus for each group

Group

Mean (Fe ppm)

Standard Deviation

Standard Error

n

AD

8.59

2.83

1.07

7

WT

8.11

4.17

1.47

8

AD_CBD

9.44

4.27

1.61

7

WT_CBD

15.29

7.91

2.80

8

Standard Deviation – population standard deviation (measure of uncertainty in regards to every sample in a given group);
standard error of the mean - estimates variability between sample

Iron is implicated along with Cu and Zn to be enriched in areas of enhanced plaque
pathology, such as the hippocampus (Lovell et al. 1998) and yet there is no significant
increase or decrease in Fe concentrations in the hippocampus of an AD affected brain when
compared to a WT brain (Table 17). This can suggest that levels of Fe are more tightly
regulated in the hippocampus and Fe concentrations associated with AD could be
experiencing accumulations or deficiencies elsewhere in the brain. Therefore, it can be
interpreted that the average Fe concentration in the hippocampus is not closely linked to AD
processes.
Table 17 - The t test generated p value for each comparative group’s (vs) average Fe concentration in the
hippocampus

Group (vs)

p-value

AD vs WT

0.80

AD_CBD vs AD

0.67

AD_CBD vs WT_CBD

0.11

WT_CBD vs WT

0.04

WT vs AD_CBD

0.55

AD vs WT_CBD

0.05

Cannabidiol treatment is seen to significantly increase the concentration of Fe in the
hippocampus in a WT brain where an untreated brain had an average Fe concentration of 8.11
± 2.83 ppm (2 STD. ERR.; n=8) and a treated one increased to 15.29 ± 7.91 ppm (2 STD.
ERR.; n=8). A higher concentration of Fe in the hippocampus is studied in Deibel et al.
(1996) to be indicative of a brain with AD. This suggests that the trend of CBD treatment to
significantly increase the Fe concentration in an otherwise healthy untreated WT brain is a
toxic one. The treatment of CBD in this case is effectively altering a WT brain into a brain
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that exhibits AD trends, in the context of the study by Deibel et al. (1996). This is shown by
the increase in Fe concentration when WT brains are treated with CBD which represents
enriched levels of Fe indicative of enhanced plaque pathology seen in AD (Greenough et al.
2013). Further study is necessary to examine this trend with a larger sample size to determine
the level of toxicity in WT mice treated with CBD in relation to Fe concentrations in the
hippocampus. It could be that initial, short-term use of CBD is a therapeutic treatment to AD
suffering brains to achieve metal ion homeostasis but a long-term treatment could prove to
introduce toxic levels of metals into the brain.
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3.3.3 Iron in the cerebellum
Iron is analysed to have an overall trend of enrichment in the cerebellum across every brain in
each group (Figure 26; Appendix 6). Average Fe concentrations for the cerebellum were
calculated for each of the 30 brains (Appendix 2). Following these calculations, the average
value for each of the four groups was achieved (Table 18). The Fe concentration in the
cerebellum of an AD mouse brain 11.28 ± 3.83 ppm (2 STD. ERR.; n=7) when compared to a
WT mouse brain 10.41 ± 2.89 ppm (2 STD. ERR.; n=8) is the only region of the brain
analysed to have a slightly higher concentration (Figure 29). This increase is not statistically
significant (Table 19) and is again supported by Deibel et al. (1996) which analysed no
significant increase or decrease in metal concentration in the cerebellum of an AD patient
when compared to healthy controls. However, due to it being the only region in the brain in
this study to display a higher metal concentration in the AD brain it is an important trend. The
increased Fe concentration in the cerebellum of the AD mice brains can be indicating a
higher concentration of plaques and implicating Fe as a larger player in the formation of
senile plaques. This is further supported by Bourassa et al. (2013) where Fe levels in plaques
of patients with severe AD were found to be elevated.
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AD

WT

AD CBD

WT CBD

Figure 29 - Average Fe concentrations (ppm) in the cerebellum for each group

Table 18 - Average Fe concentrations in the cerebellum for each group

Group

Mean (Fe ppm)

Standard Deviation

Standard Error

n

AD

11.28

3.83

1.45

7

WT

10.41

2.89

1.02

8

AD_CBD

12.74

3.17

1.20

7

WT_CBD

19.03

6.21

2.20

8

Standard Deviation – population standard deviation (measure of uncertainty in regards to every sample in a given group);
standard error of the mean - estimates variability between sample
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Table 19 - The t test generated p value for each comparative group’s (vs) average Fe concentration in the cerebellum

Group (vs)

p-value

AD vs WT

0.62

AD_CBD vs AD

0.45

AD_CBD vs WT_CBD

0.03

WT_CBD vs WT

0.0031

WT vs AD_CBD

0.16

AD vs WT_CBD

0.01

Cannabidiol treatment to WT mouse brains was found to significantly increase Fe
concentration in the cerebellum (Table 19). This is compared with an insignificant increase in
Fe concentration in the cerebellum when AD brains are treated with CBD. This can further
support the notion that short-term CBD treatment could have a therapeutic advantage to kickstart metal-ion homeostasis in AD brains but long-term treatment on a recovering (closer to
WT) brain could have a potentially toxic effect.

3.4 GENERAL TRENDS
The general trend of Cu, Zn and Fe concentrations in the whole brain, cerebellum and
hippocampus regions in AD mouse brains compared to WT is a slight decrease in metal
concentration in the AD brain. This is indicating that AD brains are deficient in metals which
can be a direct result of mechanism failure such as a lack of ceruloplasmin resulting in
interrupted Cu distribution in an AD brain (Snaedal et al. 1998).
The most significant general trend in Cu, Zn and Fe concentrations in the whole brain,
cerebellum and hippocampus regions is the increase of concentrations when AD and WT
mice are treated with CBD. Every concentration in each of the three regions for every group
experienced an increase when treated with CBD. As discussed, this could be indicative of a
short-term therapeutic benefit of CBD in promoting metal ion homeostasis in affected brains.
Alternatively, it is seen to increase the concentration of metals in WT, healthy brains to
potentially toxic levels and therefore long-term use of CBD treatment could prove dangerous
to brains after their metal levels reach homeostasis.
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3.5 LIMITATIONS AND RECOMMENDATIONS
The limitations of this study begin with the preparation of each sample brain in the
cryosectioning process. When mounting the sample onto the specimen holder in the cryostat,
the holder itself is oriented using mechanical adjustments completely independent on the user
carrying it out. This introduces large margins of error as the mechanical adjustment is
undertaken solely by the user and their judgement of how flush the blade is with the sample.
The limitations here are that any number of samples could have been cut at an angle to the
blade and are therefore not a true representative cross-section when imaged. This could also
result in the bio maps displaying misleading accumulations or deficiencies, which would then
result in inaccurate average concentrations when the data is extracted in ArcGIS. Therefore,
future studies using the cryosectioning process should form a method to reduce the amount of
mechanical adjustment necessary and try and substitute where possible.
In the LA ICP-MS method there are limitations on sample contamination directly before,
during and after analysis. Errors in the form of contamination of the sample through
accidentally touching it directly and so on could result in misleading accumulations or
deficiencies of metals in the bio maps and corresponding average concentrations of regions.
These errors are relatively unavoidable but future studies should address them in their method
to lower the risk of them occurring.
In the method of extracting data from the regions of the cerebellum and hippocampus in
ArcGIS there exist limitations that can be affecting the average concentrations studied. The
use of only one polygon to highlight and select the data in the hippocampus and cerebellum
for each of the 30 samples limits the data extracted due to possible variation of each sample.
The samples are each georeferenced to a base brain which the polygon was created from but
each brain did not ‘fit’ perfectly over the base brain and therefore data extraction could be
taking from slightly different areas each time. In the time constraints of this study it was not
feasible to create an individual polygon for each sample’s cerebellum and hippocampus but
future studies can achieve this to provide more valid results.
Further studies would benefit from using plaque staining methods on a similar section of
brain and comparing that to the metal distribution map to more effectively draw conclusions
about plaque pathology.
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CHAPTER 4 – CONCLUSIONS
The distribution of metals, specifically Cu, Fe and Zn, can indicate regions of interest in
regards to AD processes. Metal concentration maps were produced to study metal distribution
and provide further insight into their link with AD. The use of CBD as a treatment for AD
was also studied in regards to metal distribution to shed light on the effect a treatment has on
Cu, Fe and Zn. The LA ICP-MS method for analysis in this study was used to map the metal
distribution of Cu, Fe and Zn in treated and untreated APPxPS1 and WT mice. The metal
distribution maps created for each sample brain for Cu, Fe and Zn provided an important tool
to identify general accumulation and deficiency trends in the brain. However, it was difficult
to define a trend that was unique and indicative to one group for each metal. Therefore, using
ArcGIS was found to be a beneficial method to extract data from specific regions to draw
conclusions.
The APPxPS1 mice were found to have on average lower Cu, Fe and Zn concentrations in the
whole brain, cerebellum and hippocampus regions when compared to WT mice. Whilst not
statistically significant, these results convey a general trend when comparing AD affected and
WT brains. The only exception to this was the average Fe concentration in the cerebellum of
APPxPS1 mice with AD found to be slightly higher when compared to WT mice brains.
Overall, the APPxPS1 mice with AD were found to be deficient in metals when compared to
WT which could be due to the failure of metal regulatory mechanisms in AD.
Treatment of CBD to both APPxPS1 mice brains with AD and WT mice brains were found to
generally increase the average concentration of metals in the brain. These results were mostly
statistically significant but it highlights an interesting trend for future studies to analyse
further. The concentration of Fe in the cerebellum was found to be significantly increased in
treated WT mice brains when compared to untreated WT mice brains (p= 0.0031). The
potential beneficial effect of CBD treatment is seen in the ability to increase average metal
concentrations of Cu, Fe and Zn in a metal deficient AD brain. However, the potential for the
CBD treatment to disrupt metal homeostasis and increase toxicity is seen in the dramatic
increase in average metal concentration when otherwise healthy brains are treated. Therefore,
a CBD treatment could prove therapeutic to AD affected brains but treatment of CBD to
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healthy brains could have the potential for toxicity to arise and the chance for
neurodegeneration to occur.
Limitations in this study in sample preparation, analysis and post analysis data manipulation
include the potential for error during mechanical adjustments in cryosectioning and operator
error in ArcGIS when defining regions. Future studies should aim to address these limitations
to produce more accurate results. This can include using an automatic adjustment process in
cryosectioning to reduce error when cutting the sample and developing a more refined
method in ArcGIS to define regions. Future studies benefit from the metal distribution maps
created in this study through the ability to identify general trends of accumulation and
deficiency to address in further research. The comparison of average metal concentrations
found in this study will also prove beneficial to the further understanding of metals and their
interaction with AD processes. The metal concentration maps can be utilised as an indicator
of regions where metal regulatory mechanisms are failing in AD including transporters of
metals found in the brain. Further studies would benefit from using plaque staining methods
on a similar section of brain and comparing that to the metal distribution map to more
effectively draw conclusions about plaque pathology.
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APPENDICES
APPENDIX 1: AVERAGE CONCENTRATIONS – CU
Cerebellum
Sample
234
235
243
247
248
256
257
258
259
260
261
262
263
264
265
267
270
274
280
281
282
283
290
291
292
296
297
298
299
305

Cu (ppm)
9.4
3.01
8.06
4.62
4.55
6.11
6.18
4.54
10.83
5.43
3.18
6.11
9.51
5.99
4.66
5.39
11.35
5.5
5.21
4.59
4.18
3.77
3.63
5.39
5.67
6.01
5.73
4.9
4.17
3.85

Group
WT
AD
WT_CBD
WT_CBD
AD_CBD
AD
WT
AD
WT_CBD
WT
WT
WT
AD_CBD
WT_CBD
AD_CBD
AD_CBD
WT_CBD
AD
WT
AD_CBD
WT_CBD
AD_CBD
AD
WT
WT
AD_CBD
WT_CBD
WT_CBD
AD
AD
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Hippocampus
Sample
234
235
243
247
248
256
257
258
259
260
261
262
263
264
265
267
270
274
280
281
282
283
290
291
292
296
297
298
299
305

Cu (ppm)
10.87
11.31
5.96
9.98
7.33
5.35
6.61
10.21
29.35
9.51
7.39
17.21
4.37
18.57
4.32
6.66
8.87
6.68
5.63
3.23
4.35
5.71
3.46
6.12
5.85
8.45
6
5.81
4.02
3.7

Group
WT
AD
WT_CBD
WT_CBD
AD_CBD
AD
WT
AD
WT_CBD
WT
WT
WT
AD_CBD
WT_CBD
AD_CBD
AD_CBD
WT_CBD
AD
WT
AD_CBD
WT_CBD
AD_CBD
AD
WT
WT
AD_CBD
WT_CBD
WT_CBD
AD
AD
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Whole brain
Sample
234
235
243
247
248
256
257
258
259
260
261
262
263
264
265
267
270
274
280
281
282
283
290
291
292
296
297
298
299
305

Cu (ppm)
2.2
1.51
3.29
4.51
3.62
3.6
2.73
3.77
6.48
3.07
2.37
6.11
4.61
5.89
3.39
3.81
9.11
4.36
3.85
2.56
3.46
3.36
2.39
4.24
5.3
4.89
4.14
3.67
3.37
2.83

Group
WT
AD
WT_CBD
WT_CBD
AD_CBD
AD
WT
AD
WT_CBD
WT
WT
WT
AD_CBD
WT_CBD
AD_CBD
AD_CBD
WT_CBD
AD
WT
AD_CBD
WT_CBD
AD_CBD
AD
WT
WT
AD_CBD
WT_CBD
WT_CBD
AD
AD
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APPENDIX 2: AVERAGE CONCENTRATIONS – FE
Cerebellum
Sample
234
235
243
247
248
256
257
258
259
260
261
262
263
264
265
267
270
274
280
281
282
283
290
291
292
296
297
298
299
305

Fe (ppm)
9.56
6.05
15.22
11.67
12.86
10.04
10.73
6.66
20.96
8.02
5.95
10.44
11.65
21.15
13.22
11.34
21.13
13.78
11.91
12.35
12.78
8.67
12.07
15.87
10.78
19.09
31.23
18.12
14.89
15.5

Group
WT
AD
WT_CBD
WT_CBD
AD_CBD
AD
WT
AD
WT_CBD
WT
WT
WT
AD_CBD
WT_CBD
AD_CBD
AD_CBD
WT_CBD
AD
WT
AD_CBD
WT_CBD
AD_CBD
AD
WT
WT
AD_CBD
WT_CBD
WT_CBD
AD
AD
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Hippocampus
Sample
234
235
243
247
248
256
257
258
259
260
261
262
263
264
265
267
270
274
280
281
282
283
290
291
292
296
297
298
299
305

Fe (ppm)
5.82
8.21
19.69
9.22
8.96
5.6
3.87
6
31.03
3.89
6.58
9.05
5.93
6.13
11.07
8.56
18.96
11.55
9.1
8.6
10.21
4.97
9.66
16.66
9.92
17.98
14.95
12.09
6.38
12.75

Group
WT
AD
WT_CBD
WT_CBD
AD_CBD
AD
WT
AD
WT_CBD
WT
WT
WT
AD_CBD
WT_CBD
AD_CBD
AD_CBD
WT_CBD
AD
WT
AD_CBD
WT_CBD
AD_CBD
AD
WT
WT
AD_CBD
WT_CBD
WT_CBD
AD
AD
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Whole brain
Sample
234
235
243
247
248
256
257
258
259
260
261
262
263
264
265
267
270
274
280
281
282
283
290
291
292
296
297
298
299
305

Fe (ppm)
0
7.04
7.57
4.61
4.93
0
0
0
1.71
0
0
0.03
0
0
1.56
1.63
9.2
1.97
5.59
3.81
2.58
0
1.89
7.37
3.3
5.71
5.51
2.28
3.16
0.97

Group
WT
AD
WT_CBD
WT_CBD
AD_CBD
AD
WT
AD
WT_CBD
WT
WT
WT
AD_CBD
WT_CBD
AD_CBD
AD_CBD
WT_CBD
AD
WT
AD_CBD
WT_CBD
AD_CBD
AD
WT
WT
AD_CBD
WT_CBD
WT_CBD
AD
AD
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APPENDIX 3: AVERAGE CONCENTRATIONS – ZN
Cerebellum
Sample
234
235
243
247
248
256
257
258
259
260
261
262
263
264
265
267
270
274
280
281
282
283
290
291
292
296
297
298
299
305

Zn (ppm)
5.07
2.5
2.37
6.44
9.86
0
0
3.01
0
0
0
0.57
0
0
4.03
4.01
11.65
7.08
8.36
4.2
3.57
0
0
6.99
5.65
16.02
9.98
2.54
0.085
6.56

Group
WT
AD
WT_CBD
WT_CBD
AD_CBD
AD
WT
AD
WT_CBD
WT
WT
WT
AD_CBD
WT_CBD
AD_CBD
AD_CBD
WT_CBD
AD
WT
AD_CBD
WT_CBD
AD_CBD
AD
WT
WT
AD_CBD
WT_CBD
WT_CBD
AD
AD
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Hippocampus
Sample
234
235
243
247
248
256
257
258
259
260
261
262
263
264
265
267
270
274
280
281
282
283
290
291
292
296
297
298
299
305

Zn (ppm)
9.93
0
0
6.63
7.48
0
0
0.81
0
0
0
1.6
0
0
3.82
3.65
13.69
7.16
8.04
7.63
3.31
0
0
6.94
5.26
21.24
9.55
2.6
0
8.08

Group
WT
AD
WT_CBD
WT_CBD
AD_CBD
AD
WT
AD
WT_CBD
WT
WT
WT
AD_CBD
WT_CBD
AD_CBD
AD_CBD
WT_CBD
AD
WT
AD_CBD
WT_CBD
AD_CBD
AD
WT
WT
AD_CBD
WT_CBD
WT_CBD
AD
AD
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Whole brain
Sample
234
235
243
247
248
256
257
258
259
260
261
262
263
264
265
267
270
274
280
281
282
283
290
291
292
296
297
298
299
305

Zn (ppm)
1.7
0
0.096
5.37
7.53
0
0
1.83
0
0
0
0
0
0
2.21
2.84
16.29
8.91
8.38
7
2.33
0
0
6.55
7.32
14.56
13.83
3.16
1.91
3.38

Group
WT
AD
WT_CBD
WT_CBD
AD_CBD
AD
WT
AD
WT_CBD
WT
WT
WT
AD_CBD
WT_CBD
AD_CBD
AD_CBD
WT_CBD
AD
WT
AD_CBD
WT_CBD
AD_CBD
AD
WT
WT
AD_CBD
WT_CBD
WT_CBD
AD
AD
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APPENDIX 4: METAL DISTRIBUTION MAPS - CU CONCENTRATIONS
APPxPS1 brains (AD affected)
235:

256:

258:

274:

290:

299:
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305:

WT brains (healthy)
234:

257:

260:

261:

262:

280:
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291:

292:
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APPxPS1 (AD affected) brains treated with cannabidiol (CBD)
248:

263:

265:

267:

281:

283:

296:
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WT (healthy) brains treated with CBD
243:

247:

259:

264:

270:

282:

82

297:

298:
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APPENDIX 5: METAL DISTRIBUTION MAPS - ZN CONCENTRATIONS
APPxPS1 brains (AD affected)
235:

256:

258:

274:

290:

299:
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305:
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WT brains (healthy)
234:

257:

260:

261:

262:

280:
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291:

292:
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APPxPS1 (AD affected) brains treated with CBD
248:

263:

265:

267:

281:

283:
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296:
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WT (healthy) brains treated with CBD
243:

247:

259:

264:

270:

282:

90

297:

298:
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APPENDIX 6: METAL DISTRIBUTION MAPS - FE CONCENTRATIONS
APPxPS1 brains (AD affected)
235:

256:

258:

274:

290:

299:
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305:
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WT brains (healthy)
234:

257:

260:

261:

262:

280:
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291:

292:
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APPxPS1 (AD affected) brains treated with CBD
248:

263:

265:

267:

281:

283:
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296:
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WT (healthy) brains treated with CBD
243:

247:

259:

264:

270:

282:

98

297:

298:

99

APPENDIX 7: METHODOLOGY WORKFLOWS
Cryosectioning preparation
Each of the left sagittal side mice brains were stored in separate vials of 30% sucrose in a
fridge environment at ~3°C until preparation for cryosectioning. Four brains could be
completed per day averaging ~7 hours on the cryostat and therefore four brains were prepared
for cryosectioning at a time. Each brain would undergo preparations as follows:
1.

Appropriate personal protection equipment (PPE) of standard gloves, lab gown, safety

glasses and completely enclosed shoes are necessary before any preparations are undertaken
in the PC3 laboratory.
2.

Tweezers are used to retrieve the brain out of the vial and the brain is laid

immediately onto a paper towel to reduce excess sucrose.
3.

The left sagittal side of the brain is then positioned with tweezers where the flat and

most central side of the brain is lying flat against a sample mould.
4.

OCT (freezing agent) is then used to cover the brain and fill the mould so the OCT is

flush with the surface of the mould. Any bubbles resulting from this process are removed
with tweezers extremely carefully.
5.

Vials previously containing the brains are disposed of in the appropriate biological

hazard bin
6.

The sample moulds containing the brains are then taken to the cryostat where the

chamber temperature is set to -15°C where the freezing agent will activate and completely
freeze the samples for cryosectioning.
7.

A blank mould is filled with OCT to provide a base for the samples so that the blade

can reach and section it properly (this will be important later)
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Cryosectioning
With each sample now frozen in the cryostat chamber ready to be sectioned, the specimen
holder temperature is set to -18°C, the width of cutting is set to 45µm and process set to
‘sectioning’. The chamber light is turned on and while fixing the specimen to the specimen
holder the blade guard must always be on and handle lock on when the blade is installed.
Each sample is positioned and sectioned as follows:
1.

Appropriate personal protection equipment (PPE) of standard gloves, lab gown, safety

glasses and completely enclosed shoes are necessary before any preparations are undertaken
in the PC3 laboratory.
2.

Twelve blank gelatine coated slides are marked with the date, a number (from #1

through to #12) and its sample number (eg #262) and positioned within reaching distance on
top of the cryostat in sequence. Slides #1 - #6 will be used for laser ablation and slides #7 #12 will be stored in a deep freezer for further studies.
3.

The blank mould is to be secured to the specimen base using a small amount of OCT

to act as a base that will be used for every sample. Two small paintbrushes and one large
paintbrush are to be found in the chamber and must be kept in the chamber at all times.
4.

The sample is to then be taken out of its mould and secured to the base of OCT

(taking care of the orientation desired – in this case the cerebellum is on the right).
5.

The specimen base is then to be secured into the specimen holder (again taking care

of orientation).
6.

The blade is then to be taken out of its holder and secured (extremely carefully) into

place and the blade guard to be removed.
7.

To make sure the sample is flush with the blade, take the handle off lock and rotate it

to move it forward (in 45µm widths) until the first slice of sample is achieved. If the cut has
only been made on the left side, then the specimen holder needs to be moved further to the
right and so on. Orientate the specimen holder as accurately as possible and then section a
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couple of slices to make sure it is only the brain sample being cut and not any excess OCT on
top of the sample (excess OCT around the sample can be cut away using a simple razor blade
or similar).
8.

Once the sample is appropriately orientated the sections are ready for the slides. As a

section is cut it will curl into itself unless a small paintbrush is used to keep it flat. Using one
small paintbrush to keep it flat and another for positioning, fully cut the section and position
it onto a side of the surface where it is easily able to be affixed to the corresponding slide.
9.

For the first section cut take the slide labelled #1 and affix it in an orientation desired

(in this case 4 sections are required for each slide so section 1 is to be positioned on the top
hand right corner of the slide, section 2 on the top hand left, section 3 on bottom hand right
and section 4 on bottom hand left).
10.

Section 1 should be cut and affixed to each slide of #1 - #12 before section 2 is to be

placed.
11.

When each of the twelve slides has 4 sections affixed to them then the sample is

finished with section 1 being closest to the centre of the brain and section 4 being closest to
the left side of the brain.
12.

The remaining sample, if any, is to be cut and disposed of with any other waste in the

appropriate biological waste bin.
13.

When the last section is cut the chamber is to be completely cleaned and rid of any

waste and the paintbrushes left in the chamber and the blade uninstalled and stored safely in
its compartment next to the cryostat. The lock position is to be used on the handle and the
chamber turned off.
14.

All of slides with fresh sample on them are to be stored in a fume hood overnight to

dry and then stored in labelled sample boxes. The slides going to the deep freezer are to be
promptly stored there. The slides to be ablated can be stored at room temperature until further
analysing is required.
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Laser ablation and ICP-MS
After all the samples were cryosectioned and stored in the appropriately labelled sample
boxes they were transported to the ICP-MS lab for analysing. In a singular session, 4 samples
are able to be analysed with standards in-between each and a NIST, taking approximately 20
hours. The 5th slide of each sample is to be used to preserve experiment viability by reducing
bias. Each run will be set up as follows:
1.

Take out the stage and remove the holder from it and position on it the NIST (612),

the fifth slide of four samples and the slide of lamb brain standards from which B, C, D, E, F
and G will be used (necessary for quantification). Secure onto the holder with blu-tack.
2.

Replace the holder in the stage and check that the top of the samples are flush with the

stage before inserting. Fasten the stage into place.
3.

Check that the correct cones (Ni high sensitivity cones) are installed and that the N₂

and He cylinders have at least ~500psi. Check the Ar tank as well and then turn on to build
up pressure.
4.

Turn on the nitrogen, water chiller and laser and purge the lines with He for 10

minutes and N₂ for 20 minutes before running the experiment.
5.

Open the program NWR and run ‘home stages’

6.

Each line created for both standards and samples needs to be created with the

properties of J/cm² = 0.8, spot size = 50µm, rep rate = 20Hz and scan speed of 200µm.
7.

For each sample, 5 lines of B, C, D, E, F and G will need to run before and after.

Therefore, for a run of four samples there needs to be 5 x 5 lines created for each of the B, C,
D, E, F and G standards.
8.

For each sample it is necessary to find the furthest left of the sample (x₁), the furthest

right (x₂), the uppermost of the sample (y₁), the bottom of the sample (y₂) and the focus at
either end of the sample (z₁ and z₂ respectively).
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9.

With these measurements the number of lines required for a sample can be

determined from (y₂ - y₁)/0.05. The duration of the laser per line can be determined from (x₂
- x₁)/0.2. The time taken between lines can be measured by running the experiment without
the laser enabled and using a timer to record how many seconds it takes from the end of the
first line until the start of the second time. With every measurement recorded from above it is
possible to determine the entire time necessary for the sample with the equation: (No. of
lines)(Duration per line + time taken between lines) + 45.
10.

The NIST (612) will have a straight line created running from the left side to the right

side. The properties on the NIST (612) line are as follows: Scan speed = 5 µm/sec, fluence =
5 J/cm2, rep rate = 5 Hz, spot size = 65 µm
11.

Making sure the plasma is turned on, He at 650mL/s, N₂ purged and online, Tv2 cup

calibrated and laser emission on, an autotune can be completed on the NIST (612).
12.

Once the autotune is successful a lab book can be set up. Individual lab books for

each sample work best with standards run before each sample on each lab book and for that
last sample standards are to be run before and after. Analytes to be collected are Cu, C, P, Co,
Zn and Fe.
13.

The experiment can now run and will so for ~20 hours after pressing play.

14.

At the experiments end, data is to be exported into the appropriate folder and

everything turned off.

Imaging software and manipulation of data
For standards:
1. Import each file for the standards (in this study there were 6) as “time, intensity” and make
sure the box for ‘continuous data (one file=one image) remains unchecked
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2. Select the element of interest to work with
3. For the first section of standards go to ‘select data’ and select the 5 boxes for each of the
six lines of standard (corresponding to B – G)
4. Click ‘export data’ and export as a .xlsx file
5. In Excel you can now calculate the average of each section for the standards
For sample:
1. Import sample data file as comma “time, intensity” and check the box for ‘continuous
data (one file=one image)
2. Select the element of interest to work with
3. Change all parameters to reflect the experiment including the individual split and start
for each sample
4. Enter in x variable and intercept derived from standards run before and after and click
‘quantify’
5. Change scale to a maximum value that best reflects the concentration of the element
chosen
6. Change the rotation and reflection to desired position

Extracting data using ArcGIS software as instructed by Alex Pescud
(University of Wollongong)
1.

Turn on the “Spatial Adjustment” Tool bar

2.

Select “Spatial Adjustment”

3.

Within ArcMap, load in the following layers:
a.

Base Brain

b.

Referenced Raster dataset
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4.

c.

Raw XY point data

d.

The section of the brain you are working with e.g. BBhippocampus

You will now need to load in the raw XY data that was exported from the

ImageEditor software. These files point files are not currently referenced.
5.

Re-symbolise the shapefile points to Quantities

6.

Spatially adjust the point file to the previously referenced raster

7.

Select the point shapefile and from the editor toolbar, select “Start Editing”

8.

Ignore the spatial reference messages

9.

Select the “New Displacement Tool Link”.

10.

Select equivalent points on the point shapefile that match the previously referenced

raster file
11.

Click a corner on the point shapefile and then click on the corresponding corner of the

raster
12.

Once you are happy with the links, select the “Spatial Adjustment” menu and click

“Set Adjust Data…”
13.

Select all features and click “OK”

14.

Select the “Spatial Adjustment” menu again and click “Adjust”. The points should

now match the spatial extent of the previously referenced raster.
15.

Click the “Selection” menu and select “Select By Location” option.

16.

Set the parameters to select all the points within the brain region of choice

106

17.

Click “OK”

18.

The points should be selected (bright blue)

19.

From the “Editor Toolbar” select “Save Edits.

20.

Export selected values to a table.

21.

Right click the point layer > Selection > Copy Records For Selected Features

22.

Paste the values in to excel
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